Don L. Gibbons, M.D., Ph.D.

Peer-Reviewed Articles

1. Grippin AJ, Marconi C, Copling S, Li N, Braun C, Woody C, Young E, Gupta P, Wang M, Wu A, Jeong SD, Soni D, Weidert F, Xie C, Goldenberg E, Kim A, Zhao C, DeVries A, Castillo P, Lohray R, Rooney MK, Schrank BR, Wang Y, Ma Y, Chang E, Kouzy R, Dyson K, Jafarnia J, Nariman N, Gladish G, New J, Argueta A, Amaya D, Thomas N, Doty A, Chen J, Copling N, Alatrash G, Simon J, Davies AB, Dennis W, Liang R, Lewis J, Wei X, Rinsurongkawong W, Vaporciyan AA, Johns A, Lee J, Lee JH, Sun R, Sharma P, Tran H, Zhang J, Gibbons DL, Wargo J, Kim BYS, Heymach JV, Mendez-Gomez HR, Jiang W, Sayour EJ, Lin SH. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature, 2025. e-Pub 2025. PMID: 41125896.
2. Zheng MM, Xia Y, Pan K, Sun F, Tan AC, Dong XR, Tu HY, Tang LB, Li YS, Yin K, Borgeaud M, Singhal S, Zhu E, Zhang J, Nilsson M, Wu J, Gibbons DL, Wakelee H, Neal JW, Lee J, Vaporciyan AA, Ringsurongkawong W, Tran HT, Zhang RZ, Zhang T, Zhou Q, Zhong WZ, Li W, Zhang YC, Riess JW, Addeo A, Heymach JV, Myall N, Tan D, Wu YL, Le X. The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study. Ann Oncol, 2025. e-Pub 2025. PMID: 41125209.
3. Aminu M, Zhu B, Vokes N, Chen H, Hong L, Li J, Fujimoto J, Chaib M, Yang Y, Wang B, Poteete A, Nilsson MB, Le X, Cascone T, Jaffray D, Navin N, Wang T, Byers LA, Gibbons DL, Heymach J, Chen K, Cheng C, Zhang J, Wu J. CoCo-ST detects global and local biological structures in spatial transcriptomics datasets. Nat Cell Biol, 2025. e-Pub 2025. PMID: 41083603.
4. Zhang, B, Shah, K, Parma, M, Wang, K, Singhi, EK, Lewis, WE, Rivera, MJ, Altan, M, Pozadzides, JV, Le, X, Vokes, N, Fossella, FV, O'Brien, BJ, Wang, C, Tom, MC, Beckham, TH, Swanson, T, Bronk, JK, Lin, SH, Vega, MF, Jacome, J, Halliday, A, Vailati Negrao, M, Zhang, J, Gibbons, DL, Heymach, JV, Byers, LA, Gay, CM. Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC—A Real-World Case Series. Journal of Thoracic Oncology 20(8):1131-1138, 2025. e-Pub 2025. PMID: 40126456.
5. Hong L, Di Federico A, Liu B, Cooper AJ, Alessi JV, Clark P, Rinsurongkawong W, Young C, Li H, Qin K, Aminu M, Santo V, Elamin Y, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Lee JJ, Le X, Wu J, Roy-Chowdhuri S, Routbort MJ, Futreal PA, Heymach JV, Awad MM, Schoenfeld AJ, Zhang J, Ricciuti B, Deng L, Vokes NI. Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study. J Thorac Oncol, 2025. e-Pub 2025. PMID: 40716572.
6. Saad MB, Al-Tashi Q, Hong L, Verma V, Li W, Boiarsky D, Li S, Petranovic M, Wu CC, Carter BW, Shroff GS, Cascone T, Le X, Elamin YY, Altan M, Heeke S, Sheshadri A, Chang JY, Lee PP, Liao Z, Gibbons DL, Vaporciyan AA, Lee JJ, Wistuba II, Haymaker C, Mirjalili S, Jaffray D, Gainor JF, Lou Y, Di Federico A, Pecci F, Awad M, Ricciuti B, Heymach JV, Vokes NI, Zhang J, Wu J. Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC. Nat Commun 16(1):6828, 2025. e-Pub 2025. PMID: 40707438.
7. Mitchell KG, Lee Y, Deboever N, Negrao MV, Tran HT, Parra E, Byers L, Reuben A, Federico L, Bernatchez C, Wang J, Antonoff MB, Vaporciyan AA, Swisher SG, Cascone T, Wistuba II, Heymach JV, Gibbons DL, Zhang J, McGrail DJ, Sepesi B, Haymaker CL. Intratumoral neutrophil-to-lymphocyte ratio is mirrored by circulating neutrophil-to-lymphocyte ratio in non-small cell lung cancer. J Immunother Cancer 13(6), 2025. e-Pub 2025. PMID: 40555561.
8. Zhu B, Chen P, Aminu M, Li JR, Fujimoto J, Tian Y, Hong L, Chen H, Hu X, Li C, Vokes N, Moreira AL, Gibbons DL, Solis Soto LM, Parra Cuentas ER, Shi O, Diao S, Ye J, Rojas FR, Vilar E, Maitra A, Chen K, Navin N, Nilsson M, Huang B, Heeke S, Zhang J, Haymaker CL, Velcheti V, Sterman DH, Kochat V, Padron WI, Alexandrov LB, Wei Z, Le X, Wang L, Fukuoka J, Lee JJ, Wistuba II, Pass HI, Davis M, Hanash S, Cheng C, Dubinett S, Spira A, Rai K, Lippman SM, Futreal PA, Heymach JV, Reuben A, Wu J, Zhang J. Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception. Cancer Cell 43(6):1125-1140.e10, 2025. e-Pub 2025. PMID: 40345189.
9. Altan M, Sui D, Xu C, Simon GR, Sulihem ST, Malveaux D, Ponce D, Rinsurongkawong W, Rinsurongkawong V, Lee JJ, Zhang J, Gibbons DL, Vaporciyan AA, Heymach JV, Santorelli ML, Burke T, Williams LA. PD-L1 Testing, Treatment Patterns, and Clinical Outcomes Among Patients with Metastatic NSCLC at an Academic Medical Center, 2017-2021. J Immunother Precis Oncol 8(2):161-171, 2025. e-Pub 2025. PMID: 40235643.
10. Li H, Salehjahromi M, Godoy MCB, Qin K, Plummer CM, Zhang Z, Hong L, Heeke S, Le X, Vokes N, Zhang B, Araujo HA, Altan M, Wu CC, Antonoff MB, Ostrin EJ, Gibbons DL, Heymach JV, Lee JJ, Gerber DE, Wu J, Zhang J. Lung Cancer Risk Prediction in Patients with Persistent Pulmonary Nodules Using the Brock Model and Sybil Model. Cancers (Basel) 17(9), 2025. e-Pub 2025. PMID: 40361426.
11. Cai, X, Cho, JY, Chen, L, Liu, Y, Ji, F, Salgado, K, Ge, S, Yang, D, Yu, H, Shao, J, Futreal, A, Sepesi, B, Gibbons, DL, Chen, Y, Wang, G, Cheng, C, Meng, W, Zhang, J, Hsiao, A, Xia, T. Enriched pathways in gut microbiome predict response to immune checkpoint inhibitor treatment across demographic regions and various cancer types. iScience 28(4), 2025. e-Pub 2025. PMID: 40151642.
12. Heeke, S, Gandhi, S, Tran, HT, Lam, VK, Byers, LA, Gibbons, DL, Gay, CM, Altan, M, Antonoff, MB, Le, X, Tu, J, Saad, M, Pek, M, Poh, J, Ngeow, KC, Tsao, A, Cascone, T, Vailati Negrao, M, Wu, J, Blumenschein, GR, Heymach, JV, Elamin, YY. Longitudinal Tracking of ALK-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA. JTO Clinical and Research Reports 6(4), 2025. e-Pub 2025. PMID: 40160974.
13. Zhang B, Shah KB, Parma M, Wang K, Singhi EK, Lewis W, Rivera M, Altan M, Pozadzides J, Le X, Vokes N, Fossella F, O'Brien B, Wang C, Tom MC, Beckham T, Swanson T, Bronk J, Lin SH, Vega MF, Jacome J, Halliday A, Negrao M, Zhang J, Gibbons DL, Heymach JV, Byers LA, Gay CM. Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC-A Real-World Case Series: Case Report. J Thorac Oncol, 2025. e-Pub 2025. PMID: 40126456.
14. Vailati Negrao, M, Paula, AG, Molkentine, D, Hover, LD, Nilsson, M, Vokes, N, Engstrom, LD, Calinisan, A, Briere, DM, Waters, L, Hallin, J, Diao, L, Altan, M, Blumenschein, GR, Skoulidis, F, Wang, J, Kopetz, S, Hong, DS, Gibbons, DL, Olson, P, Christensen, JG, Heymach, JV. Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. Clinical Cancer Research 31(6):1069-1081, 2025. e-Pub 2025. PMID: 39804166.
15. Di Federico, A, Hong, L, Elkrief, A, Thummalapalli, R, Cooper, AJ, Ricciuti, B, Digumarthy, S, Alessi, JV, Gogia, P, Pecci, F, Makarem, M, Gandhi, M, Garbo, E, Saini, A, De Giglio, A, Favorito, V, Scalera, S, Cipriani, L, Marinelli, D, Haradon, D, Nguyen, T, Haradon, J, Voligny, E, Vaz, VR, Gelsomino, F, Sperandi, F, Melotti, B, Ladanyi, M, Zhang, J, Gibbons, DL, Heymach, JV, Nishino, M, Lindsay, J, Rodig, SJ, Pfaff, KL, Sholl, LM, Wang, X, Johnson, BE, Jänne, PA, Rekhtman, N, Maugeri-Saccà, M, Heist, RS, Ardizzoni, A, Awad, MM, Arbour, KC, Schoenfeld, AJ, Vokes, N, Luo, J. Lung adenocarcinomas with mucinous histology. Annals of Oncology 36(3):297-308, 2025. e-Pub 2025. PMID: 39637943.
16. Le, X, Patel, JD, Shum, E, Baik, C, Sanborn, RE, Shu, CA, Kim, C, Fidler, MJ, Hall, R, Elamin, YY, Tu, J, Blumenschein, GR, Zhang, J, Gibbons, DL, Gay, CM, Mohindra, N, Chae, YK, Boumber, YA, Sabari, JK, Santana-Davila, R, Rogosin, S, Herzberg, B, Creelan, BC, Pellini, B, Tanvetyanon, T, Heeke, S, Hernandez, M, Gray, J, Saltos, A, Heymach, JV. A Multicenter Open-Label Randomized Phase II Study of Osimertinib with and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR -Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial). Journal of Clinical Oncology 43(4):403-411, 2025. e-Pub 2025. PMID: 39378386.
17. Rahal, Z, Liu, Y, Peng, F, Yang, S, Jamal, M, Sharma, M, Moreno, H, Damania, A, Wong, M, Ross, MC, Sinjab, A, Zhou, T, Chen, M, Reischle, IT, Feng, J, Chukwuocha, C, Tang, EL, Abaya, C, Lim, JK, Leung, CH, Lin, HY, Deboever, N, Lee, JJ, Sepesi, B, Gibbons, DL, Wargo, J, Fujimoto, J, Wang, L, Petrosino, JF, Ajami, NJ, Jenq, RR, Moghaddam, SM, Cascone, T, Hoffman, KL, Kadara, HN. Inflammation Mediated by Gut Microbiome Alterations Promotes Lung Cancer Development and an Immunosuppressed Tumor Microenvironment. Cancer Immunology Research 12(12):1736-1752, 2024. e-Pub 2024. PMID: 39269772.
18. Sujit, S, Aminu, M, Karpinets, T, Chen, P, Saad, M, Salehjahromi, M, Boom, JD, Qayati, M, George, JM, Allen, H, Antonoff, MB, Hong, L, Hu, X, Heeke, S, Tran, HT, Le, X, Elamin, YY, Altan, M, Vokes, N, Sheshadri, A, Lin, J, Zhang, J, Lu, Y, Behrens, MC, Godoy, M, Wu, CC, Chang, JY, Chung, C, Jaffray, D, Wistuba, II, Lee, JJ, Vaporciyan, AA, Gibbons, DL, Heymach, J, Zhang, J, Cascone, T, Wu, J. Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights. Nature communications 15(1), 2024. e-Pub 2024. PMID: 38605064.
19. Valensin C, Cote EJM, Pereira-Carvalho D, Gardner RA, Nishku G, Giles CL, Gill C, Brockbank A, Story L, Shennan AH, Suff N, Gibbons DL, Tribe RM. INSIGHT-2: mechanistic studies into pregnancy complications and their impact on maternal and child health-study protocol. Reprod Health 21(1):177, 2024. e-Pub 2024. PMID: 39609862.
20. Araujo HA, Pechuan-Jorge X, Zhou T, Do MT, Hu X, Rojas Alvarez FR, Salvatierra ME, Ibarguen HP, Lee R, Raghulan R, Shah H, Moreno Ayala MA, Chen K, Tovbis Shifrin N, Wu S, Solis Soto LM, Negrao MV, Gibbons DL, Hong DS, Roth JA, Heymach JV, Zhang J, Jiang J, Singh M, Smith JAM, Quintana E, Skoulidis F. Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung Cancer. Cancer Discov 14(11):2183-2208, 2024. e-Pub 2024. PMID: 38975897.
21. Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbo F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Leighl NB, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Janne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature 635(8038):462-471, 2024. e-Pub 2024. PMID: 39385035.
22. Zhou N, Leung CH, William WN Jr, Weissferdt A, Pataer A, Godoy MCB, Carter BW, Fossella FV, Tsao AS, Blumenschein GR, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Tran HT, Wu J, Solis Soto LM, Kadara H, Swisher SG, Vaporciyan AA, Gibbons DL, Lin HY, Lee JJ, Heymach JV, Negrao MV, Sepesi B, Cascone T. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer 12(10), 2024. e-Pub 2024. PMID: 39448200.
23. Stewart CA, Diao L, Xi Y, Wang R, Ramkumar K, Serrano AG, Tanimoto A, Rodriguez BL, Morris BB, Shen L, Zhang B, Yang Y, Hamad SH, Cardnell RJ, Duarte A Jr, Sahu M, Novegil VY, Weissman BE, Frumovitz M, Kalhor N, Solis Soto L, da Rocha P, Vokes N, Gibbons DL, Wang J, Heymach JV, Glisson B, Byers LA, Gay CM. YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities. Clin Cancer Res 30(20):4743-4754, 2024. e-Pub 2024. PMID: 39150543.
24. Rodriguez, B, Huang, J, Gibson, L, Fradette, JJ, Chen, HI, Koyano, K, Cortez, C, Li, B, Ho, C, Ashique, AM, Lin, VY, Crawley, S, Roda, JM, Chen, P, Fan, B, Kim, J, Sissons, J, Sitrin, J, Kaplan, DD, Gibbons, DL, Rivera, LB. Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors. Molecular cancer therapeutics 23(8):1144-1158, 2024. e-Pub 2024. PMID: 38648067.
25. Seth, S, Chen, R, Liu, Y, Fujimoto, J, Hong, L, Reuben, A, Varghese, S, Behrens, MC, McDowell, TL, Solis Soto, LM, Haymaker, CL, Weissferdt, A, Kalhor, N, Wu, J, Le, X, Vokes, N, Cheng, C, Heymach, JV, Gibbons, DL, Futreal, A, Wistuba, II, Kadara, HN, Zhang, J, Moran, C, Zhang, J. Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomes. Cancer Innovation 3(3), 2024. e-Pub 2024. PMID: 38947760.
26. Montorsi L, Pitcher MJ, Zhao Y, Dionisi C, Demonti A, Tull TJ, Dhami P, Ellis RJ, Bishop C, Sanderson JD, Jain S, D'Cruz D, Gibbons DL, Winkler TH, Bemark M, Ciccarelli FD, Spencer J. Double-negative B cells and DNASE1L3 colocalise with microbiota in gut-associated lymphoid tissue. Nat Commun 15(1):4051, 2024. e-Pub 2024. PMID: 38744839.
27. Feldman, HA, Sepesi, B, Leung, CH, Lin, Y, Weissferdt, A, Pataer, A, William Jr, WN, Walsh, GL, Rice, DC, Roth, JA, Mehran, RJ, Hofstetter, WL, Antonoff, MB, Rajaram, R, Gibbons, DL, Lee, JJ, Heymach, JV, Vaporciyan, AA, Swisher, SG, Cascone, T. Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery 167(4):1444-1453.e4, 2024. e-Pub 2024. PMID: 37816395.
28. Salehjahromi, M, Karpinets, T, Sujit, S, Qayati, M, Chen, P, Aminu, M, Saad, MB, Bandyopadhyay, R, Hong, L, Sheshadri, A, Lin, J, Antonoff, MB, Sepesi, B, Ostrin, EJ, Toumazis, I, Huang, P, Cheng, C, Cascone, T, Vokes, N, Behrens, C, Siewerdsen, JH, Hazle, JD, Chang, JY, Zhang, J, Lu, Y, Godoy, M, Chung, C, Jaffray, D, Wistuba, II, Lee, JJ, Vaporciyan, AA, Gibbons, DL, Gladish, G, Heymach, JV, Wu, CC, Zhang, J, Wu, J. Synthetic PET from CT improves diagnosis and prognosis for lung cancer. Cell Reports Medicine 5(3), 2024. e-Pub 2024. PMID: 38471502.
29. Qin, K, Wang, K, Li, S, Hong, L, Padmakumar, P, Waree, R, Hubert, SM, Le, X, Vokes, N, Rai, K, Vaporciyan, AA, Gibbons, DL, Heymach, JV, Lee, JJ, Woodman, SE, Chung, C, Jaffray, D, Altan, M, Lou, Y, Zhang, J. Clinical Benefit from Docetaxel +/− Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy. Cancers 16(5), 2024. e-Pub 2024. PMID: 38473297.
30. Tran, HT, Heeke, S, Sujit, S, Vokes, N, Zhang, J, Aminu, M, Lam, VK, Vaporciyan, AA, Swisher, SG, Godoy, M, Cascone, T, Sepesi, B, Gibbons, DL, Wu, J, Heymach, JV. Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer. Annals of Oncology 35(2):183-189, 2024. e-Pub 2024. PMID: 37992871.
31. Zhang, B, Lewis, WE, Stewart, C, Morris, BB, Solis Soto, LM, Serrano, A, Xi, Y, Wang, Q, Lopez, ER, Concannon, K, Heeke, S, Tang, X, Raso, G, Cardnell, R, Vokes, N, Blumenschein, GR, Elamin, YY, Fosella, F, Tsao, A, Skoulidis, F, Hume, CB, Sasak, K, Lewis, J, Rinsurongkawong, W, Rinsurongkawong, V, Lee, JJ, Tran, HT, Zhang, J, Gibbons, DL, Vaporciyan, AA, Wang, J, Park, K, Heymach, JV, Byers, LA, Gay, CM, Le, X. Brief Report. JTO Clinical and Research Reports 5(2), 2024. e-Pub 2024. PMID: 38357092.
32. Li, H, Hu, X, Ning, M, Fuller, GN, Stewart, J, Gilliam, JC, Wu, J, Le, X, Vaporciyan, AA, Lee, JJ, Gibbons, DL, Heymach, JV, Futreal, A, Zhang, J. Case report. Frontiers in Oncology 14, 2024. e-Pub 2024. PMID: 38590653.
33. Wang K, Du R, Myall NJ, Lewis WE, Uy N, Hong L, Skoulidis F, Byers LA, Tsao A, Cascone T, Pozadzides J, Tu J, Negrao MV, Gibbons DL, Park K, Rinsurongkawong W, Lee JJ, Gandara D, Behl D, Shu CA, Riess JW, Baik C, Wakelee HA, Vaporciyan AA, Heymach JV, Zhang J, Le X. BRIEF REPORT: Real-world efficacy and safety of amivantamab for EGFR-mutant non-small cell lung cancer (NSCLC). J Thorac Oncol:S1556-0864(23)02376-6, 2023. PMID: 38012986.
34. Thummalapalli R, Ricciuti B, Bandlamudi C, Muldoon D, Rizvi H, Elkrief A, Luo J, Alessi JV, Pecci F, Lamberti G, Di Federico A, Hong L, Zhang J, Heymach JV, Gibbons DL, Plodkowski AJ, Ravichandran V, Donoghue MTA, Vanderbilt C, Ladanyi M, Rudin CM, Kris MG, Riely GJ, Chaft JE, Hellmann MD, Vokes NI, Awad MM, Schoenfeld AJ. Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Clin Cancer Res 29(21):4408-4418, 2023. e-Pub 2023. PMID: 37432985.
35. Altan M, Soto F, Zhong LL, Akhmedzhanov FO, Wilson NR, Zarifa A, Albittar AA, Yang V, Lewis J, Rinsurongkawong W, Jack Lee J, Rinsurongkawong V, Zhang J, Gibbons DL, Vaporciyan AA, Jennings K, Khawaja F, Faiz SA, Shannon VR, Shroff G, Godoy MCB, Daver NG, Gandhi S, Mendoza TR, Naing A, Daniel-MacDougall C, Heymach JV, Sheshadri A. Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience. Oncologist 28(11):E1065-E1074, 2023. e-Pub 2023. PMID: 37156009.
36. Diao S, Chen P, Showkatian E, Bandyopadhyay R, Rojas FR, Zhu B, Hong L, Aminu M, Saad MB, Salehjahromi M, Muneer A, Sujit SJ, Behrens C, Gibbons DL, Heymach JV, Kalhor N, Wistuba II, Solis Soto LM, Zhang J, Qin W, Wu J. Automated Cellular-Level Dual Global Fusion of Whole-Slide Imaging for Lung Adenocarcinoma Prognosis. Cancers (Basel) 15(19), 2023. e-Pub 2023. PMID: 37835518.
37. Hung CN, Chen M, DeArmond DT, Chiu CH, Limboy CA, Tan X, Kusi M, Chou CW, Lin LL, Zhang Z, Wang CM, Chen CL, Mitsuya K, Osmulski PA, Gaczynska ME, Kirma NB, Vadlamudi RK, Gibbons DL, Warner S, Brenner AJ, Mahadevan D, Michalek JE, Huang TH, Taverna JA. AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages. Cell Rep 42(9):113067, 2023. e-Pub 2023. PMID: 37659081.
38. Konen JM, Rodriguez BL, Wu H, Fradette JJ, Gibson L, Diao L, Wang J, Schmidt S, Wistuba II, Zhang J, Gibbons DL. Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti-PD-1 resistance in non-small cell lung cancer. J Clin Invest 133(17), 2023. e-Pub 2023. PMID: 37655662.
39. Chen P, Rojas FR, Hu X, Serrano A, Zhu B, Chen H, Hong L, Bandyoyadhyay R, Aminu M, Kalhor N, Lee JJ, El Hussein S, Khoury JD, Pass HI, Moreira AL, Velcheti V, Sterman DH, Fukuoka J, Tabata K, Su D, Ying L, Gibbons DL, Heymach JV, Wistuba II, Fujimoto J, Solis Soto LM, Zhang J, Wu J. Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma. Mod Pathol 36(12):100326. e-Pub 2023. PMID: 37678674.
40. Wang K, Kumar T, Wang J, Minussi DC, Sei E, Li J, Tran TM, Thennavan A, Hu M, Casasent AK, Xiao Z, Bai S, Yang L, King LM, Shah V, Kristel P, van der Borden CL, Marks JR, Zhao Y, Zurita AJ, Aparicio A, Chapin B, Ye J, Zhang J, Gibbons DL, Sawyer E, Thompson AM, Futreal A, Hwang ES, Wesseling J, Lips EH, Navin NE. Archival single-cell genomics reveals persistent subclones during DCIS progression. Cell 186(18):3968-3982.e15, 2023. e-Pub 2023. PMID: 37586362.
41. Perez-Oquendo, M, Manshouri, R, Tian, Y, Fradette, JJ, Rodriguez, B, Kundu, S, Gibbons, DL. ZEB1 is regulated by K811 acetylation to promote stability, NuRD complex interactions, EMT, and NSCLC metastasis. Molecular Cancer Research 21(8):779-794, 2023. e-Pub 2023. PMID: 37255406.
42. Wang K, Du R, Roy-Chowdhuri S, Li ZT, Hong L, Vokes N, Elamin YY, Hume CB, Skoulidis F, Gay CM, Blumenschein G, Fossella FV, Tsao A, Zhang J, Karachaliou N, O'Brate A, Gann CN, Lewis J, Rinsurongkawong W, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Altan M, Le X. Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC. JTO Clin Res Rep 4(8):100533, 2023. e-Pub 2023. PMID: 37649681.
43. Saad MB, Hong L, Aminu M, Vokes NI, Chen P, Salehjahromi M, Qin K, Sujit SJ, Lu X, Young E, Al-Tashi Q, Qureshi R, Wu CC, Carter BW, Lin SH, Lee PP, Gandhi S, Chang JY, Li R, Gensheimer MF, Wakelee HA, Neal JW, Lee HS, Cheng C, Velcheti V, Lou Y, Petranovic M, Rinsurongkawong W, Le X, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Antonoff MB, Sepesi B, Lewis J, Wistuba II, Hazle JD, Chung C, Jaffray D, Gibbons DL, Vaporciyan A, Lee JJ, Heymach JV, Zhang J, Wu J. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study. Lancet Digit Health 5(7):e404-e420, 2023. e-Pub 2023. PMID: 37268451.
44. Reyes-Castro RA, Chen SY, Seemann J, Kundu ST, Gibbons DL, Arur S. Phosphorylated nuclear DICER1 promotes open chromatin state and lineage plasticity of AT2 tumor cells in lung adenocarcinomas. Sci Adv 9(30):eadf6210, 2023. e-Pub 2023. PMID: 37494452.
45. Xiao GY, Tan X, Rodriguez BL, Gibbons DL, Wang S, Wu C, Liu X, Yu J, Vasquez ME, Tran HT, Xu J, Russell WK, Haymaker C, Lee Y, Zhang J, Solis L, Wistuba II, Kurie JM. EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer. Proc Natl Acad Sci U S A 120(28):e2220276120, 2023. e-Pub 2023. PMID: 37406091.
46. Ravi A, Hellmann MD, Arniella MB, Holton M, Freeman SS, Naranbhai V, Stewart C, Leshchiner I, Kim J, Akiyama Y, Griffin AT, Vokes NI, Sakhi M, Kamesan V, Rizvi H, Ricciuti B, Forde PM, Anagnostou V, Riess JW, Gibbons DL, Pennell NA, Velcheti V, Digumarthy SR, Mino-Kenudson M, Califano A, Heymach JV, Herbst RS, Brahmer JR, Schalper KA, Velculescu VE, Henick BS, Rizvi N, Jänne PA, Awad MM, Chow A, Greenbaum BD, Luksza M, Shaw AT, Wolchok J, Hacohen N, Getz G, Gainor JF. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nat Genet 55(5):807-819, 2023. e-Pub 2023. PMID: 37024582.
47. Perez-Oquendo M, Manshouri R, Tian Y, Fradette JJ, Rodriguez BL, Kundu ST, Gibbons DL. ZEB1 is Regulated by K811 Acetylation to Promote Stability, NuRD Complex Interactions, EMT, and NSCLC Metastasis. Mol Cancer Res:OF1-OF16. e-Pub 2023. PMID: 37255406.
48. Patel SA, Nilsson MB, Yang Y, Le X, Tran H, Elamin YY, Yu X, Zhang F, Poteete A, Ren X, Shen L, Wang J, Moghaddam SJ, Cascone T, Curran M, Gibbons DL, Heymach JV. IL-6 mediates suppression of T and NK cells function in EMT-associated TKI-resistant EGFR mutant NSCLC<. Clin Cancer Res 29(7):1292-1304, 2023. e-Pub 2023. PMID: 36595561.
49. Parra ER, Zhang J, Jiang M, Tamegnon A, Pandurengan RK, Behrens C, Solis L, Haymaker C, Heymach JV, Moran C, Lee JJ, Gibbons D, Wistuba II. Immune cellular patterns of distribution affect outcomes of patients with non-small cell lung cancer. Nat Commun 14(1):2364, 2023. e-Pub 2023. PMID: 37185575.
50. Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med 29(3):593-604, 2023. e-Pub 2023. PMID: 36928818.
51. Nilsson MB, Yang Y, Heeke S, Patel SA, Poteete A, Udagawa H, Elamin YY, Moran CA, Kashima Y, Arumugam T, Yu X, Ren X, Diao L, Shen L, Wang Q, Zhang M, Robichaux JP, Shi C, Pfeil AN, Tran H, Gibbons DL, Bock J, Wang J, Minna JD, Kobayashi SS, Le X, Heymach JV. CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. Cancer Cell 41(2):340-355.e6, 2023. e-Pub 2023. PMID: 36787696.
52. Hong L, Aminu M, Li S, Lu X, Petranovic M, Saad MB, Chen P, Qin K, Varghese S, Rinsurongkawong W, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Gandhi SJ, Lin SH, Lee PP, Carter BW, Wu CC, Antonoff MB, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Le X, Jack Lee J, Roy-Chowdhuri S, Routbort MJ, Gainor JF, Heymach JV, Lou Y, Wu J, Zhang J, Vokes NI. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. Nat Commun 14(1):695, 2023. e-Pub 2023. PMID: 36755027.
53. Qureshi, S, Arani, N, Parvathareddy, V, Tchakarov, A, Abdelrahim, M, Suarez-Almazor, M, Zhang, J, Gibbons, DL, Heymach, JV, Altan, M, Abudayyeh, A. Case Report. Frontiers in Nephrology 3, 2023. e-Pub 2023. PMID: 37675380.
54. Vokes NI, Galan Cobo A, Fernandez-Chas M, Molkentine D, Treviño S, Druker V, Qian Y, Patel S, Schmidt S, Hong L, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee JJ, Negrao MV, Gibbons DL, Vaporciyan A, Le X, Wu J, Zhang J, Rigney U, Iyer S, Dean E, Heymach JV. ATM mutations associate with distinct co-mutational patterns and therapeutic vulnerabilities in NSCLC. Clin Cancer Res 29(23):4958-4972, 2023. e-Pub 2023. PMID: 37733794.
55. Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC. Cancer Discov 13(7):1556-1571, 2023. e-Pub 2023. PMID: 37068173.
56. De B, Farooqi AS, Mitchell KG, Ludmir EB, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee JJ, Swisher SG, Gibbons DL, Zhang J, Le X, Elamin YY, Gomez DR, Ning MS, Lin SH, Liao Z, Chang JY, Vaporciyan AA, Heymach JV, Antonoff MB, Gandhi SJ. Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival. JCO Precis Oncol 7:e2200540, 2023. e-Pub 2023. PMID: 36716413.
57. Qureshi S, Arani N, Parvathareddy V, Tchakarov A, Abdelrahim M, Suarez-Almazor M, Zhang J, Gibbons DL, Heymach J, Altan M, Abudayyeh A. Case Report: Immune checkpoint inhibitor-induced multiorgan vasculitis successfully treated with rituximab. Front Nephrol 3:1168614, 2023. e-Pub 2023. PMID: 37675380.
58. Rodriguez BL, Chen L, Li Y, Miao S, Peng DH, Fradette JJ, Diao L, Konen JM, Alvarez FRR, Solis LM, Yi X, Padhye A, Gibson LA, Ochieng JK, Zhou X, Wang J, Gibbons DL. Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance. Front Immunol 14:1161869, 2023. e-Pub 2023. PMID: 37449205.
59. Liu Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Skoulidis F, Chang JY, Liao Z, Gomez DR, O'Reilly M, Heymach JV, Tsao AS, Lin SH. Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Lung Cancer 174:112-117, 2022. e-Pub 2022. PMID: 36371941.
60. Kang J, Chun J, Hwang JS, Pan C, Li J, Boese AC, Young I, Malin CM, Kang Y, Gibbons DL, Sica G, Fu H, Ramalingam SS, Jin L, Kang S. EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancer. Cell Rep 41(11):111827, 2022. e-Pub 2022. PMID: 36516759.
61. Sepesi B, Zhou N, William WN, Lin HY, Leung CH, Weissferdt A, Mitchell KG, Pataer A, Walsh GL, Rice DC, Roth JA, Mehran RJ, Hofstetter WL, Antonoff MB, Rajaram R, Negrao MV, Tsao AS, Gibbons DL, Lee JJ, Heymach JV, Vaporciyan AA, Swisher SG, Cascone T. Surgical outcomes after nivolumab or nivolumab with ipilimumab treatment in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 164(5):1327-1337, 2022. e-Pub 2022. PMID: 35190177.
62. Akhave N, Zhang J, Bayley E, Frank M, Chiou SH, Behrens C, Chen R, Hu X, Parra ER, Lee WC, Swisher S, Solis L, Weissferdt A, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Heymach JV, Lee JJ, Wistuba II, Andrew Futreal P, Zhang J, Fujimoto J, Reuben A. Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment. Lung Cancer 172:19-28, 2022. e-Pub 2022. PMID: 35973335.
63. Bajaj R, Rodriguez BL, Russell WK, Warner AN, Diao L, Wang J, Raso MG, Lu W, Khan K, Solis LS, Batra H, Tang X, Fradette JF, Kundu ST, Gibbons DL. Impad1 and Syt11 work in an epistatic pathway that regulates EMT-mediated vesicular trafficking to drive lung cancer invasion and metastasis. Cell Rep 40(13):111429, 2022. e-Pub 2022. PMID: 36170810.
64. Hong L, Lewis WE, Nilsson M, Patel S, Varghese S, Rivera MJ, Du RR, Chen P, Kemp HN, Rinsurongkawong W, Heeke S, Spelman AR, Elamin YY, Negrao MV, Sepesi B, Gibbons DL, Lee JJ, Wu J, Vokes NI, Heymach JV, Zhang J, Le X. Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma. Cancers (Basel) 14(14), 2022. e-Pub 2022. PMID: 35884533.
65. Elamin YY, Robichaux JP, Carter BW, Altan M, Tran H, Gibbons DL, Heeke S, Fossella FV, Lam VK, Le X, Negrao MV, Nilsson MB, Patel A, Vijayan RSK, Cross JB, Zhang J, Byers LA, Lu C, Cascone T, Feng L, Luthra R, San Lucas FA, Mantha G, Routbort M, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell 40(7):754-767.e6, 2022. e-Pub 2022. PMID: 35820397.
66. Schmidt ST, Akhave N, Knightly RE, Reuben A, Vokes N, Zhang J, Li J, Fujimoto J, Byers LA, Sanchez-Espiridion B, Diao L, Wang J, Federico L, Forget MA, McGrail DJ, Weissferdt A, Lin SY, Lee Y, Suzuki E, Kovacs JJ, Behrens C, Wistuba II, Futreal A, Vaporciyan A, Sepesi B, Heymach JV, Bernatchez C, Haymaker C, Cascone T, Zhang J, Bristow CA, Heffernan TP, Negrao MV, Gibbons DL, Team I. Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set. JCO Clin Cancer Inform 6:e2200040, 2022. e-Pub 2022. PMID: 35944232.
67. Rocha P, Zhang J, Laza-Briviesca R, Cruz-Bermúdez A, Bota-Rabassedas N, Sanchez-Espiridion B, Yoshimura K, Behrens C, Lu W, Tang X, Pataer A, Parra ER, Haymaker C, Fujimoto J, Swisher SG, Heymach JV, Gibbons DL, Lee JJ, Sepesi B, Cascone T, Solis LM, Provencio M, Wistuba II, Kadara H. Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy and chemoimmunotherapy in resectable NSCLC. Clin Cancer Res 28(11):2461-2473, 2022. e-Pub 2022. PMID: 35394499.
68. Liu Y, Zhang Z, Rinsurongkawong W, Gay CM, Le X, Ning MS, Lewis J, Rinsurongkawong V, Lee JJ, Roth J, Swisher S, Gandhi S, Lee PP, Gibbons DL, Vaporciyan AA, Heymach JV, Zhang J, Lin SH. Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab. JAMA Netw Open 5(6):e2215589, 2022. e-Pub 2022. PMID: 35666500.
69. Cascone T, Fradette J, Pradhan M, Gibbons DL. Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer. Cold Spring Harb Perspect Med 12(5), 2022. e-Pub 2021. PMID: 34580079.
70. Altan M, Singhi EK, Worst M, Carter BW, Leung CH, Lee JJ, Presley CJ, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Zhang J, Gibbons DL, Vaporciyan AA, Heymach JV, Mott FE. Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer. Clin Lung Cancer 23(3):236-243, 2022. e-Pub 2022. PMID: 35216923.
71. Kundu ST, Rodriguez BL, Gibson LA, Warner AN, Perez MG, Bajaj R, Fradette JJ, Class CA, Solis LM, Rojas Alvarez FR, Wistuba II, Diao L, Chen F, Sachdeva M, Wang J, Kirsch DG, Creighton CJ, Gibbons DL. The microRNA-183/96/182 cluster inhibits lung cancer progression and metastasis by inducing an interleukin-2-mediated antitumor CD8+ cytotoxic T-cell response. Genes Dev 36(9-10):582-600, 2022. e-Pub 2022. PMID: 35654454.
72. Chen R, Li J, Fujimoto J, Hong L, Hu X, Quek K, Tang M, Mitra A, Behrens C, Chow CW, Jiang P, Little LD, Gumbs C, Song X, Zhang J, Tan D, Heymach JV, Wistuba I, Futreal PA, Gibbons DL, Byers LA, Zhang J, Reuben A. Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma. J Exp Clin Cancer Res 41(1):172, 2022. e-Pub 2022. PMID: 35546239.
73. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 13(1):1970, 2022. e-Pub 2022. PMID: 35413951.
74. Elamin YY, Robichaux JP, Carter BW, Altan M, Gibbons DL, Fossella FV, Lam VK, Patel AB, Negrao MV, Le X, Mott FE, Zhang J, Feng L, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for Patients with HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. J Clin Oncol 40(7):JCO2101113, 2022. e-Pub 2021. PMID: 34550757.
75. Deboever, N, McGrail, DJ, Lee, Y, Tran, HT, Mitchell, KG, Antonoff, MB, Hofstetter, WL, Mehran, RJ, Rice, DC, Roth, JA, Swisher, SG, Vaporciyan, AA, Walsh, GL, Bernatchez, C, Vailati Negrao, M, Zhang, J, Wistuba, II, Heymach, JV, Cascone, T, Gibbons, DL, Haymaker, CL, Sepesi, B. Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection. Lung Cancer 164:69-75, 2022. e-Pub 2022. PMID: 35038676.
76. Shah P, Forget MA, Frank ML, Jiang P, Sakellariou-Thompson D, Federico L, Khairullah R, Neutzler CA, Wistuba I, Chow CB, Long Y, Fujimoto J, Lin SY, Maitra A, Negrao MV, Mitchell KG, Weissferdt A, Vaporciyan AA, Cascone T, Roth JA, Zhang J, Sepesi B, Gibbons DL, Heymach JV, Haymaker CL, McGrail DJ, Reuben A, Bernatchez C. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. J Immunother Cancer 10(2), 2022. e-Pub 2022. PMID: 35110355.
77. Li H, Xiao Y, Li Q, Yao J, Yuan X, Zhang Y, Yin X, Saito Y, Fan H, Li P, Kuo WL, Halpin A, Gibbons DL, Yagita H, Zhao Z, Pang D, Ren G, Yee C, Lee JJ, Yu D. The Allergy Mediator Histamine Confers Resistance to Immunotherapy in Cancer Patients via Activation of the Macrophage Histamine Receptor H1. Cancer Cell 40(1):36-52.e9, 2022. e-Pub 2021. PMID: 34822775.
78. Federico L, McGrail DJ, Bentebibel SE, Haymaker C, Ravelli A, Forget MA, Karpinets T, Jiang P, Reuben A, Negrao MV, Li J, Khairullah R, Zhang J, Weissferdt A, Vaporciyan AA, Antonoff MB, Walsh G, Lin SY, Futreal A, Wistuba I, Roth J, Byers LA, Gaudreau PO, Uraoka N, Cruz AF, Dejima H, Lazcano RN, Solis LM, Parra ER, Lee JJ, Swisher S, Cascone T, Heymach JV, Zhang J, Sepesi B, Gibbons DL, Bernatchez C. Distinct Tumor-infiltrating Lymphocyte Landscapes are Associated with Clinical Outcomes in Localized Non-small Cell Lung Cancer. Ann Oncol S0923-7534(21):04519-1, 2022. e-Pub 2022. PMID: 34653632.
79. Rodriguez BL, Gibbons DL. MEK inhibition invigorates chemoimmunotherapy by tumor mitophagy-induced CXCL10 expression. Cell Rep Med 3(1):100506, 2022. e-Pub 2022. PMID: 35106515.
80. Mohd Zaki A, Hadingham A, Flaviani F, Haque Y, Mi JD, Finucane D, Dalla Valle G, Mason AJ, Saqi M, Gibbons DL, Tribe RM. Neutrophils Dominate the Cervical Immune Cell Population in Pregnancy and Their Transcriptome Correlates With the Microbial Vaginal Environment. Front Microbiol 13:904451, 2022. e-Pub 2022. PMID: 35774454.
81. Sun, H, Cao, S, Mashl, RJ, Mo, CK, Zaccaria, S, Wendl, MC, Davies, S, Bailey, MH, Primeau, T, Hoog, J, Mudd, JL, Dean, DA, Patidar, R, Chen, L, Wyczalkowski, MA, Jayasinghe, R, Rodrigues, FM, Terekhanova, NV, Li, Y, Lim, KH, Wang-Gillam, A, Van Tine, BA, Ma, C, Aft, R, Fuh, KC, Schwarz, JK, Roth, JA, Akcakanat, A, Chen, H, Dai, B, Gibbons, DL, Ha, MJ, Jensen, VB, Kim, M, Kopetz, S, Menter, DG, Meraz, I, Sorokin, A, Tapia, C, Wang, J, Westin, SN, Xi, Y, Yang, F, Yap, TA, Yennu Nanda, VG, Zhang, X, Zheng, X, Davies, MA, Fang, B, Meric-Bernstam, F. Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment. Nature communications 12(1), 2021. e-Pub 2021. PMID: 34429404.
82. Tang M, Abbas HA, Negrao MV, Ramineni M, Hu X, Hubert SM, Fujimoto J, Reuben A, Varghese S, Zhang J, Li J, Chow CW, Mao X, Song X, Lee WC, Wu J, Little L, Gumbs C, Behrens C, Moran C, Weissferdt A, Lee JJ, Sepesi B, Swisher S, Cheng C, Kurie J, Gibbons D, Heymach JV, Wistuba II, Futreal PA, Kalhor N, Zhang J. The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nat Commun 12(1):7081, 2021. e-Pub 2021. PMID: 34873156.
83. Stewart CA, Gay CM, Ramkumar K, Cargill KR, Cardnell RJ, Nilsson MB, Heeke S, Park EM, Kundu ST, Diao L, Wang Q, Shen L, Xi Y, Zhang B, Della Corte CM, Fan Y, Kundu K, Gao B, Avila K, Pickering CR, Johnson FM, Zhang J, Kadara H, Minna JD, Gibbons DL, Wang J, Heymach JV, Byers LA. Lung Cancer Models Reveal SARS-CoV-2-induced EMT Contributes to COVID-19 Pathophysiology. J Thorac Oncol 16(11):1821-1839, 2021. e-Pub 2021. PMID: 34274504.
84. Chen M, Chen R, Jin Y, Li J, Hu X, Zhang J, Fujimoto J, Hubert SM, Gay CM, Zhu B, Tian Y, McGranahan N, Lee WC, George J, Hu X, Chen Y, Wu M, Behrens C, Chow CW, Pham HHN, Fukuoka J, Wu J, Parra ER, Little LD, Gumbs C, Song X, Wu CJ, Diao L, Wang Q, Cardnell R, Zhang J, Wang J, Le X, Gibbons DL, Heymach JV, Jack Lee J, William WN, Cheng C, Glisson B, Wistuba I, Andrew Futreal P, Thomas RK, Reuben A, Byers LA, Zhang J. Cold and Heterogeneous T cell Repertoire is Associated with Copy Number Aberrations and Loss of Immune Genes in Small-cell Lung Cancer. Nat Commun 12(1):6655, 2021. e-Pub 2021. PMID: 34789716.
85. Sinjab A, Han G, Treekitkarnmongkol W, Hara K, Brennan PM, Dang M, Hao D, Wang R, Dai E, Dejima H, Zhang J, Bogatenkova E, Sanchez-Espiridion B, Chang K, Little DR, Bazzi S, Tran LM, Krysan K, Behrens C, Duose DY, Parra ER, Raso MG, Solis LM, Fukuoka J, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Rosen D, Heymach JV, Scheet P, Dubinett SM, Fujimoto J, Wistuba II, Stevenson CS, Spira A, Wang L, Kadara H. Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-cell Sequencing. Cancer Discov 11(10):2506-2523, 2021. e-Pub 2021. PMID: 33972311.
86. Lu T, Zhang Z, Zhu J, Wang Y, Jiang P, Xiao X, Bernatchez C, Heymach JV, Gibbons DL, Wang J, Xu L, Reuben A, Wang T. Deep learning-based prediction of the T cell receptor-antigen binding specificity. Nat Mach Intell 3(10):864-875, 2021. e-Pub 2021. PMID: 36003885.
87. Padhye A, Konen JM, Rodriguez BL, Fradette JJ, Ochieng JK, Diao L, Wang J, Lu W, Solis LS, Batra H, Raso MG, Peoples MD, Minelli R, Carugo A, Bristow CA, Gibbons DL. Targeting CDK4 Overcomes EMT-mediated Tumor Heterogeneity and Therapeutic Resistance in KRAS Mutant Lung Cancer. JCI Insight 6(17), 2021. e-Pub 2021. PMID: 34309585.
88. Lu T, Zhang Z, Zhu J, Wang Y, Jiang P, Xiao X, Bernatchez C, Heymach JV, Gibbons DL, Wang J, Xu L, Reuben A, Wang T. Deep Learning-based Prediction of the T cell Receptor–antigen Binding Specificity. Nat Mach Intell 3:864-875, 2021. e-Pub 2021.
89. Tran HT, Lam VK, Elamin YY, Hong L, Colen R, Elshafeey NA, Hassan ISA, Altan M, Blumenschein GR, Rinsurongkawong W, Rivera MJ, Vasquez ME, Carter BW, Byers LE, Tsao AS, Gibbons DL, Fossella F, Glisson BS, Zhang J, Heymach JV. Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. JCO Precis Oncol 5:1241-1249, 2021. e-Pub 2021. PMID: 34377884.
90. Cascone T, Weissferdt A, Godoy MCB, William WN, Leung CH, Lin HY, Basu S, Yadav SS, Pataer A, Mitchell KG, Khan MAW, Shi Y, Haymaker C, Solis LM, Parra ER, Kadara H, Wistuba II, Sharma P, Allison JP, Ajami NJ, Wargo JA, Jenq RR, Gibbons DL, Lee JJ, Swisher SG, Vaporciyan AA, Heymach JV, Sepesi B. Nodal Immune Flare Mimics Nodal Disease Progression Following Neoadjuvant Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer. Nat Commun 12(1):5045, 2021. e-Pub 2021. PMID: 34413300.
91. Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, Xu H, Hu S, Sui D, Elamin YY, Le X, Goldberg ME, Murugesan K, Wu CJ, Zhang J, Barreto DS, Robichaux JP, Reuben A, Cascone T, Gay CM, Mitchell KG, Hong L, Rinsurongkawong W, Roth JA, Swisher SG, Lee J, Tsao A, Papadimitrakopoulou V, Gibbons DL, Glisson BS, Singal G, Miller VA, Alexander B, Frampton G, Albacker LA, Shames D, Zhang J, Heymach JV. Oncogene-specific Differences in Tumor Mutational Burden, PD-L1 Expression, and Outcomes from Immunotherapy in Non-small Cell Lung Cancer. J Immunother Cancer 9(8), 2021. e-Pub 2021. PMID: 34376553.
92. Rocha P, Salazar R, Zhang J, Ledesma D, Solorzano JL, Mino B, Villalobos P, Dejima H, Douse DY, Diao L, Mitchell KG, Le X, Zhang J, Weissferdt A, Parra-Cuentas E, Cascone T, Rice DC, Sepesi B, Kalhor N, Moran C, Vaporciyan A, Heymach J, Gibbons DL, Lee JJ, Kadara H, Wistuba I, Behrens C, Solis LM. Correction to: CD73 Expression Defines Immune, Molecular, and Clinicopathological Subgroups of Lung Adenocarcinoma. Cancer Immunol Immunother 70(7):1977-1978, 2021. e-Pub 2021. PMID: 33686493.
93. Joseph R, Soundararajan R, Vasaikar S, Yang F, Allton KL, Tian L, den Hollander P, Isgandarova S, Haemmerle M, Mino B, Zhou T, Shin C, Martinez-Paniagua M, Sahin AA, Rodriguez-Canales J, Gelovani J, Chang JT, Acharya G, Sood AK, Wistuba II, Gibbons DL, Solis LM, Barton MC, Varadarajan N, Rosen JM, Zhang XH, Mani SA. CD8 + T Cells Inhibit Metastasis and CXCL4 Regulates its Function. Br J Cancer 125(2):176-189, 2021. e-Pub 2021. PMID: 33795809.
94. Rocha P, Salazar R, Zhang J, Ledesma D, Solorzano JL, Mino B, Villalobos P, Dejima H, Douse DY, Diao L, Mitchell KG, Le X, Zhang J, Weissferdt A, Parra-Cuentas E, Cascone T, Rice DC, Sepesi B, Kalhor N, Moran C, Vaporciyan A, Heymach J, Gibbons DL, Lee JJ, Kadara H, Wistuba I, Behrens C, Solis LM. CD73 Expression Defines Immune, Molecular, and Clinicopathological Subgroups of Lung Adenocarcinoma. Cancer Immunol Immunother 70(7):1965-1976, 2021. e-Pub 2021. PMID: 33416944.
95. Tan X, Banerjee P, Shi L, Xiao GY, Rodriguez BL, Grzeskowiak CL, Liu X, Yu J, Gibbons DL, Russell WK, Creighton CJ, Kurie JM. p53 Loss Activates Prometastatic Secretory Vesicle Biogenesis in the Golgi. Sci Adv 7(25), 2021. e-Pub 2021. PMID: 34144984.
96. Peng DH, Rodriguez BL, Diao L, Gaudreau PO, Padhye A, Konen JM, Ochieng JK, Class CA, Fradette JJ, Gibson L, Chen L, Wang J, Byers LA, Gibbons DL. Th17 Cells Contribute to Combination MEK Inhibitor and Anti-PD-L1 Therapy Resistance in KRAS/p53 Mutant Lung Cancers. Nat Commun 12(1):2606, 2021. e-Pub 2021. PMID: 33972557.
97. Behrens C, Rocha P, Parra ER, Feng L, Rodriguez-Canales J, Solis LM, Mino B, Zhang J, Gibbons DL, Sepesi B, Rice D, Heymach JV, Moran C, Creighton CJ, Lee JJ, Kadara H, Wistuba II. Female Sex Predicts Augmented Immune Infiltration in Lung Adenocarcinoma. Clin Lung Cancer 22(3):e415-e424, 2021. e-Pub 2021. PMID: 32763065.
98. Guo HF, Bota-Rabassedas N, Terajima M, Leticia Rodriguez B, Gibbons DL, Chen Y, Banerjee P, Tsai CL, Tan X, Liu X, Yu J, Tokmina-Roszyk M, Stawikowska R, Fields GB, Miller MD, Wang X, Lee J, Dalby KN, Creighton CJ, Phillips GN, Tainer JA, Yamauchi M, Kurie JM. A Collagen Glucosyltransferase Drives Lung Adenocarcinoma Progression in Mice. Commun Biol 4(1):482, 2021. e-Pub 2021. PMID: 33875777.
99. Le X, Negrao MV, Reuben A, Federico L, Diao L, McGrail D, Nilsson M, Robichaux J, Munoz IG, Patel S, Elamin Y, Fan YH, Lee WC, Parra E, Solis Soto LM, Chen R, Li J, Karpinets T, Khairullah R, Kadara H, Behrens C, Sepesi B, Wang R, Zhu M, Wang L, Vaporciyan A, Roth J, Swisher S, Haymaker C, Zhang J, Wang J, Wong KK, Byers LA, Bernatchez C, Zhang J, Wistuba II, Gibbons DL, Akbay EA, Heymach JV. Characterization of the Immune Landscape of EGFR-mutant NSCLC Identifies CD73/adenosine Pathway as a Potential Therapeutic Target. J Thorac Oncol 16(4):583-600, 2021. e-Pub 2021. PMID: 33388477.
100. Lam VK, Zhang J, Wu CC, Tran HT, Li L, Diao L, Wang J, Rinsurongkawong W, Raymond VM, Lanman RB, Lewis J, Roarty EB, Roth J, Swisher S, Lee JJ, Gibbons DL, Papadimitrakopoulou VA, Heymach JV. Genotype-specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC. J Thorac Oncol 16(4):601-609, 2021. e-Pub 2021. PMID: 33388476.
101. Bota-Rabassedas N, Banerjee P, Niu Y, Cao W, Luo J, Xi Y, Tan X, Sheng K, Ahn YH, Lee S, Parra ER, Rodriguez-Canales J, Albritton J, Weiger M, Liu X, Guo HF, Yu J, Rodriguez BL, Firestone JJA, Mino B, Creighton CJ, Solis LM, Villalobos P, Raso MG, Sazer DW, Gibbons DL, Russell WK, Longmore GD, Wistuba II, Wang J, Chapman HA, Miller JS, Zong C, Kurie JM. Contextual Cues from Cancer Cells Govern Cancer-associated Fibroblast Heterogeneity. Cell Rep 35(3):109009, 2021. e-Pub 2021. PMID: 33882319.
102. Konen JM, Rodriguez BL, Padhye A, Ochieng JK, Gibson L, Diao L, Fowlkes NW, Fradette JJ, Peng DH, Cardnell RJ, Kovacs JJ, Wang J, Byers LA, Gibbons DL. Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-mesenchymal Transition in NSCLC. Cancer Res 81(5):1398-1412, 2021. e-Pub 2021. PMID: 33402388.
103. Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Operable Non-small Cell Lung Cancer: The Phase 2 Randomized NEOSTAR Trial. Nat Med 27(3):504-514, 2021. e-Pub 2021. PMID: 33603241.
104. Han G, Sinjab A, Hara K, Treekitkarnmongkol W, Brennan P, Chang K, Bogatenkova E, Sanchez-Espiridion B, Behrens C, Solis LM, Gao B, Girard L, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Scheet P, Fujimoto J, Shay J, Heymach JV, Minna JD, Dubinett S, Wistuba II, Stevenson CS, Spira AE, Wang L, Kadara H. Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. Cancers (Basel) 13(6):1250, 2021. e-Pub 2021. PMID: 33809063.
105. Monteiro de Oliveira Novaes JA, Hirz T, Guijarro I, Nilsson M, Pisegna MA, Poteete A, Barsoumian HB, Fradette JJ, Chen LN, Gibbons DL, Tian X, Wang J, Myers JN, McArthur MJ, Bell D, William WN, Heymach JV. Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma. Cancer Prev Res (Phila) 14(3):313-324, 2021. e-Pub 2021. PMID: 33277316.
106. Ramkumar K, Stewart CA, Cargill KR, Della Corte CM, Wang Q, Shen L, Diao L, Cardnell RJ, Peng DH, Rodriguez BL, Fan YH, Heymach JV, Wang J, Gay CM, Gibbons DL, Byers LA. AXL Inhibition Induces DNA Damage and Replication Stress in Non-small Cell lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors. Mol Cancer Res 19(3):485-497, 2021. e-Pub 2021. PMID: 33172976.
107. Grigoryan B, Sazer DW, Avila A, Albritton JL, Padhye A, Ta AH, Greenfield PT, Gibbons DL, Miller JS. Development, Characterization, and Applications of Multi-material Stereolithography Bioprinting. Sci Rep 11(1):3171, 2021. e-Pub 2021. PMID: 33542283.
108. Woo, XY, Giordano, J, Srivastava, A, Zhao, ZM, Lloyd, M, de Bruijn, R, Suh, YS, Patidar, R, Chen, L, Scherer, S, Bailey, M, Yang, CH, Cortes-Sanchez, E, Xi, Y, Wang, J, Wickramasinghe, JM, Kossenkov, AV, Rebecca, VW, Sun, H, Mashl, RJ, Davies, S, Jeon, R, Frech, C, Randjelovic, J, Rosains, J, Galimi, F, Bertotti, A, Lafferty, A, O’Farrell, AC, Modave, E, Lambrechts, D, Fang, B, Roth, JA, Meric-Bernstam, F, Davies, MA, Zheng, X, Zhang, X, Akcakanat, A, Yap, TA, Ha, MJ, Chen, H, Kopetz, S, Menter, DG, Westin, SN, Kim, M, Dai, B, Gibbons, DL, Jensen, VB, Yennu Nanda, VG, Mælandsmo, GM. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nature Genetics 53(1):86-99, 2021. e-Pub 2021. PMID: 33414553.
109. Creelan BC, Yeh TC, Kim SW, Nogami N, Kim DW, Chow LQM, Kanda S, Taylor R, Tang W, Tang M, Angell HK, Roudier MP, Marotti M, Gibbons DL. A Phase 1 Study of Gefitinib Combined with Durvalumab in EGFR TKI-naive Patients with EGFR Mutation-positive Locally Advanced/metastatic Non-small-cell Lung Cancer. Br J Cancer 124(2):383-390, 2021. e-Pub 2021. PMID: 33012782.
110. Tan X, Shi L, Banerjee P, Liu X, Guo HF, Yu J, Bota-Rabassedas N, Rodriguez BL, Gibbons DL, Russell WK, Creighton CJ, Kurie JM. A Pro-tumorigenic Secretory Pathway Activated by p53 Deficiency in Lung Adenocarcinoma. J Clin Invest 131(1), 2021. e-Pub 2021. PMID: 32931483.
111. Gaudreau PO, Negrao MV, Mitchell KG, Reuben A, Corsini EM, Li J, Karpinets TV, Wang Q, Diao L, Wang J, Federico L, Parra-Cuentas ER, Khairullah R, Behrens C, Correa AM, Gomez D, Little L, Gumbs C, Kadara HN, Fujimoto J, McGrail DJ, Vaporciyan AA, Swisher SG, Walsh G, Antonoff MB, Weissferdt A, Tran H, Roarty E, Haymaker C, Bernatchez C, Zhang J, Futreal PA, Wistuba II, Cascone T, Heymach JV, Sepesi B, Zhang J, Gibbons DL. Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. J Thorac Oncol 16(1):127-139, 2021. e-Pub 2021. PMID: 33096269.
112. Stewart CA, Gay CM, Ramkumar K, Cargill KR, Cardnell RJ, Nilsson MB, Heeke S, Park EM, Kundu ST, Diao L, Wang Q, Shen L, Xi Y, Zhang B, Della Corte CM, Fan Y, Kundu K, Gao B, Avila K, Pickering CR, Johnson FM, Zhang J, Kadara H, Minna JD, Gibbons DL, Wang J, Heymach JV, Byers LA. SARS-CoV-2 Infection Induces EMT-like Molecular Changes, Including ZEB1-mediated Repression of the Viral Receptor ACE2, in Lung Cancer Models. bioRxiv, 2021. e-Pub 2021. PMID: 32577652.
113. Lee WC, Reuben A, Hu X, McGranahan N, Chen R, Jalali A, Negrao MV, Hubert SM, Tang C, Wu CC, Lucas AS, Roh W, Suda K, Kim J, Tan AC, Peng DH, Lu W, Tang X, Chow CW, Fujimoto J, Behrens C, Kalhor N, Fukumura K, Coyle M, Thornton R, Gumbs C, Li J, Wu CJ, Little L, Roarty E, Song X, Lee JJ, Sulman EP, Rao G, Swisher S, Diao L, Wang J, Heymach JV, Huse JT, Scheet P, Wistuba II, Gibbons DL, Futreal PA, Zhang J, Gomez D, Zhang J. Multiomics Profiling of Primary Lung Cancers and Distant Metastases Reveals Immunosuppression as a Common Characteristic of Tumor Cells with Metastatic Plasticity. Genome Biol 21(1):271, 2020. e-Pub 2020. PMID: 33148332.
114. Ochieng JK, Kundu ST, Bajaj R, Leticia Rodriguez B, Fradette JJ, Gibbons DL. MBIP (MAP3K12 binding inhibitory protein) Drives NSCLC Metastasis by JNK-dependent Activation of MMPs. Oncogene 39(43):6719-6732, 2020. e-Pub 2020. PMID: 32963352.
115. Gay CM, Zhou Y, Lee JJ, Tang XM, Lu W, Wistuba II, Ferrarotto R, Gibbons DL, Glisson BS, Kies MS, Simon GR, Heymach JV, Tsao AS. A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. Oncologist 25(10):e1457-e1463, 2020. e-Pub 2020. PMID: 32608142.
116. Yamauchi M, Gibbons DL, Zong C, Fradette JJ, Bota-Rabassedas N, Kurie JM. Fibroblast Heterogeneity and its Impact on Extracellular Matrix and Immune Landscape Remodeling in Cancer. Matrix Biol 91-92:8-18, 2020. e-Pub 2020. PMID: 32442601.
117. Peng DH, Rodriguez BL, Diao L, Chen L, Wang J, Byers LA, Wei Y, Chapman HA, Yamauchi M, Behrens C, Raso G, Soto LMS, Cuentes ERP, Wistuba II, Kurie JM, Gibbons DL. Collagen Promotes Anti-PD-1/PD-L1 Resistance in Cancer Through LAIR1-dependent CD8+ T Cell Exhaustion. Nat Commun 11(1):4520, 2020. e-Pub 2020. PMID: 32908154.
118. Bajaj R, Kundu ST, Grzeskowiak CL, Fradette JJ, Scott KL, Creighton CJ, Gibbons DL. IMPAD1 and KDELR2 Drive Invasion and Metastasis by Enhancing Golgi-mediated Secretion. Oncogene 39(37):5979-5994, 2020. e-Pub 2020. PMID: 32753652.
119. Nilsson MB, Sun H, Robichaux J, Pfeifer M, McDermott U, Travers J, Diao L, Xi Y, Tong P, Shen L, Hofstad M, Kawakami M, Le X, Liu X, Fan Y, Poteete A, Hu L, Negrao MV, Tran H, Dmitrovsky E, Peng D, Gibbons DL, Wang J, Heymach JV. A YAP/FOXM1 Axis Mediates EMT-associated EGFR Inhibitor Resistance and Increased Expression of Spindle Assembly Checkpoint Components. Sci Transl Med 12(559), 2020. e-Pub 2020. PMID: 32878980.
120. Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer. J Thorac Oncol 15(9):1449-1459, 2020. e-Pub 2020. PMID: 32389639.
121. Corsini EM, Wang Q, Tran HT, Mitchell KG, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Reuben A, Vasquez ME, Bernatchez C, Wang J, Cascone T, Zhang J, Heymach JV, Gibbons DL, Haymaker CL, Sepesi B. Peripheral Cytokines are not Influenced by the Type of Surgical Approach for Non-small Cell Lung Cancer by Four Weeks Postoperatively. Lung Cancer 146:303-309, 2020. e-Pub 2020. PMID: 32619781.
122. Mitchell KG, Amini B, Wang Y, Carter BW, Godoy MCB, Parra ER, Behrens C, Villalobos P, Reuben A, Lee JJ, Weissferdt A, Moran CA, Fujimoto J, Sepesi B, Walsh GL, Vaporciyan AA, Hofstetter WL, William WN, Gibbons DL, Wang J, Hwu P, Swisher SG, Piwnica-Worms D, Kadara H, Wistuba II, Heymach JV, Peng W, Cascone T. 18F-fluorodeoxyglucose Positron Emission Tomography Correlates with Tumor Immunometabolic Phenotypes in Resected Lung Cancer. Cancer Immunol Immunother 69(8):1519-1534, 2020. e-Pub 2020. PMID: 32300858.
123. Cascone T, Sepesi B, Lin HY, Kalhor N, Parra ER, Jiang M, Godoy MCB, Zhang J, Fossella FV, Tsao AS, Lam VK, Lu C, Mott FE, Simon GR, Antonoff MB, Mehran RJ, Rice DC, Behrens C, Weissferdt A, Moran C, Vaporciyan AA, Lee JJ, Swisher SG, Gibbons DL, Wistuba II, William WN, Heymach JV. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res 26(14):3525-3536, 2020. e-Pub 2020. PMID: 32193228.
124. Gaudreau PO, Lee JJ, Heymach JV, Gibbons DL. Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report. Clin Lung Cancer 21(4):384-388, 2020. e-Pub 2020. PMID: 32299768.
125. Della Corte CM, Sen T, Gay CM, Ramkumar K, Diao L, Cardnell RJ, Rodriguez BL, Stewart CA, Papadimitrakopoulou VA, Gibson L, Fradette JJ, Wang Q, Fan Y, Peng DH, Negrao MV, Wistuba II, Fujimoto J, Solis Soto LM, Behrens C, Skoulidis F, Heymach JV, Wang J, Gibbons DL, Byers LA. STING Pathway Expression Identifies NSCLC with an Immune-Responsive Phenotype. J Thorac Oncol 15(5):777-791, 2020. e-Pub 2020. PMID: 32068166.
126. Mitchell KG, Diao L, Karpinets T, Negrao MV, Tran HT, Parra ER, Corsini EM, Reuben A, Federico L, Bernatchez C, Dejima H, Francisco-Cruz A, Wang J, Antonoff MB, Vaporciyan AA, Swisher SG, Cascone T, Wistuba II, Heymach JV, Gibbons DL, Zhang J, Haymaker CL, Sepesi B. Neutrophil Expansion Defines an Immunoinhibitory Peripheral and Intratumoral Inflammatory Milieu in Resected Non-small Cell Lung Cancer: A Descriptive Analysis of a Prospectively Immunoprofiled Cohort. J Immunother Cancer 8(1), 2020. e-Pub 2020. PMID: 32350118.
127. Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS. Phase II Trial of Concurrent Atezolizumab with Chemoradiation for Unresectable NSCLC. J Thorac Oncol 15(2):248-257, 2020. e-Pub 2020. PMID: 31778797.
128. Mitchell KG, Negrao MV, Parra ER, Li J, Zhang J, Dejima H, Vaporciyan AA, Swisher SG, Weissferdt A, Antonoff MB, Cascone T, Roarty E, Wistuba II, Heymach JV, Gibbons DL, Zhang J, Sepesi B. Lymphovascular Invasion is Associated with Mutational Burden and PD-L1 in Resected Lung Cancer. Ann Thorac Surg 109(2):358-366, 2020. e-Pub 2020. PMID: 31550464.
129. Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, Fujimoto J, Behrens C, Liu X, Wang F, Quek K, Wang C, Kheradmand F, Chen R, Chow CW, Lin H, Bernatchez C, Jalali A, Hu X, Wu CJ, Eterovic AK, Parra ER, Yusko E, Emerson R, Benzeno S, Vignali M, Wu X, Ye Y, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Cascone T, Snyder A, Wargo JA, Herbst R, Swisher S, Kadara H, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Robins H, Hwu P, Heymach JV, Sharma P, Allison JP, Baladandayuthapani V, Lee JJ, Davis MM, Wistuba II, Futreal PA, Zhang J. Comprehensive T Cell Repertoire Characterization of Non-small Cell Lung Cancer. Nat Commun 11(1):603, 2020. e-Pub 2020. PMID: 32001676.
130. Tan X, Banerjee P, Pham EA, Rutaganira FUN, Basu K, Bota-Rabassedas N, Guo HF, Grzeskowiak CL, Liu X, Yu J, Shi L, Peng DH, Rodriguez BL, Zhang J, Zheng V, Duose DY, Solis LM, Mino B, Raso MG, Behrens C, Wistuba II, Scott KL, Smith M, Nguyen K, Lam G, Choong I, Mazumdar A, Hill JL, Gibbons DL, Brown PH, Russell WK, Shokat K, Creighton CJ, Glenn JS, Kurie JM. PI4KIIIβ is a Therapeutic Target in Chromosome 1q-amplified Lung Adenocarcinoma. Sci Transl Med 12(527), 2020. e-Pub 2020. PMID: 31969487.
131. Zhang X, Zhang R, Chen H, Wang L, Ren C, Pataer A, Wu S, Meng QH, Ha MJ, Morris J, Xi Y, Wang J, Zhang J, Gibbons DL, Heymach JV, Meric-Bernstam F, Minna J, Swisher SG, Roth JA, Fang B. KRT-232 and Navitoclax Enhance Trametinib's Anti-Cancer Activity in Non-small Cell Lung Cancer Patient-derived Xenografts with KRAS Mutations. Am J Cancer Res 10(12):4464-4475, 2020. e-Pub 2020. PMID: 33415011.
132. Manshouri R, Coyaud E, Kundu ST, Peng DH, Stratton SA, Alton K, Bajaj R, Fradette JJ, Minelli R, Peoples MD, Carugo A, Chen F, Bristow C, Kovacs JJ, Barton MC, Heffernan T, Creighton CJ, Raught B, Gibbons DL. ZEB1/NuRD Complex Suppresses TBC1D2b to Stimulate E-cadherin Internalization and Promote Metastasis in Lung Cancer. Nat Commun 10(1):5125, 2019. e-Pub 2019. PMID: 31719531.
133. Kudo Y, Haymaker C, Zhang J, Reuben A, Duose DY, Fujimoto J, Roy-Chowdhuri S, Solis Soto LM, Dejima H, Parra ER, Mino B, Abraham R, Ikeda N, Vaporcyan A, Gibbons DL, Zhang J, Lang FF, Luthra R, Lee JJ, Moran C, Huse JT, Kadara H, Wistuba II. Suppressed Immune Microenvironment and Repertoire in Brain Metastases from Patients with Resected Non-small Cell Lung Cancer. Ann Oncol 30(9):1521-1530, 2019. e-Pub 2019. PMID: 31282941.
134. Negrao MV, Lam VK, Reuben A, Rubin ML, Landry LL, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Gibbons DL, Wistuba II, Papadimitrakopoulou V, Glisson BS, Blumenschein GR, Lee JJ, Heymach JV, Zhang J. PD-L1 Expression, Tumor Mutational Burden and Cancer Gene Mutations are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. J Thorac Oncol 14(6):1021-1031, 2019. e-Pub 2019. PMID: 30780001.
135. Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Welsh JW, Gibbons DL, Karam JA, Kavanagh BD, Tsao AS, Sepesi B, Swisher SG, Heymach JV. Local Consolidative Therapy vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol 37(18):1558-1565, 2019. e-Pub 2019. PMID: 31067138.
136. Sen T, Rodriguez BL, Chen L, Corte CMD, Morikawa N, Fujimoto J, Cristea S, Nguyen T, Diao L, Li L, Fan Y, Yang Y, Wang J, Glisson BS, Wistuba II, Sage J, Heymach JV, Gibbons DL, Byers LA. Targeting DNA Damage Response Promotes Anti-tumor Immunity through STING-mediated T-cell Activation in Small Cell Lung Cancer. Cancer Discov 9(5):646-661, 2019. e-Pub 2019. PMID: 30777870.
137. Konen JM, Rodriguez BL, Fradette JJ, Gibson L, Davis D, Minelli R, Peoples MD, Kovacs J, Carugo A, Bristow C, Heffernan T, Gibbons DL. Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer. Cancers (Basel) 11(4), 2019. e-Pub 2019. PMID: 30986992.
138. Padhye A, Ungewiss C, Fradette JJ, Rodriguez BL, Albritton JL, Miller JS, Gibbons DL. A Novel Ex Vivo Tumor System Identifies Src-Mediated Invasion and Metastasis in Mesenchymal Tumor Cells in Non-Small Cell Lung Cancer. Sci Rep 9(1):4819, 2019. e-Pub 2019. PMID: 30894630.
139. Peng DH, Kundu ST, Fradette JJ, Diao L, Tong P, Byers LA, Wang J, Canales JR, Villalobos PA, Mino B, Yang Y, Minelli R, Peoples MD, Bristow CA, Heffernan TP, Carugo A, Wistuba II, Gibbons DL. ZEB1 Suppression Sensitizes KRAS Mutant Cancers to MEK Inhibition by an IL17RD-Dependent Mechanism. Sci Transl Med 11(483), 2019. e-Pub 2019. PMID: 30867319.
140. Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, Lorenzi PL, Huang A, Zhao Q, Peng D, Fradette JJ, Peng DH, Ungewiss C, Roybal J, Tong P, Oba J, Skoulidis F, Peng W, Carter BW, Gay CM, Fan Y, Class CA, Zhu J, Rodriguez-Canales J, Kawakami M, Byers LA, Woodman SE, Papadimitrakopoulou VA, Dmitrovsky E, Wang J, Ullrich SE, Wistuba II, Heymach JV, Qin FX, Gibbons DL. CD38-mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discov 8(9):1156-1175, 2018. e-Pub 2018. PMID: 30012853.
141. Grzeskowiak CL, Kundu ST, Mo X, Ivanov AA, Zagorodna O, Lu H, Chapple RH, Tsang YH, Moreno D, Mosqueda M, Eterovic K, Fradette JJ, Ahmad S, Chen F, Chong Z, Chen K, Creighton CJ, Fu H, Mills GB, Gibbons DL, Scott KL. In Vivo Screening Identifies GATAD2B as a Metastasis Driver in KRAS-driven Lung Cancer. Nat Commun 9(1):2732, 2018. e-Pub 2018. PMID: 30013058.
142. Kundu ST, Grzeskowiak CL, Fradette JJ, Gibson LA, Rodriguez LB, Creighton CJ, Scott KL, Gibbons DL. TMEM106B Drives Lung Cancer Metastasis by Inducing TFEB-Dependent Lysosome Synthesis and Secretion of Cathepsins. Nat Commun 9(1):2731, 2018. e-Pub 2018. PMID: 30013069.
143. Parra ER, Villalobos P, Behrens C, Jiang M, Pataer A, Swisher SG, William WN, Zhang J, Lee J, Cascone T, Heymach JV, Forget MA, Haymaker C, Bernatchez C, Kalhor N, Weissferdt A, Moran C, Zhang J, Vaporciyan A, Gibbons DL, Sepesi B, Wistuba II. Effect of Neoadjuvant Chemotherapy on the Immune Microenvironment in Non-Small Cell Lung Carcinomas as Determined by Multiplex Immunofluorescence and Image Analysis Approaches. J Immunother Cancer 6(1):48, 2018. e-Pub 2018. PMID: 29871672.
144. Sepesi B, Nelson DB, Mitchell KG, Gibbons DL, Heymach JV, Vaporciyan AA, Swisher SG, Roszik J. Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer. Ann Thorac Surg 105(6):1621-1626, 2018. e-Pub 2018. PMID: 29510096.
145. Chen F, Zhang Y, Gibbons DL, Deneen B, Kwiatkowski DJ, Ittmann M, Creighton CJ. Pan-cancer Molecular Classes Transcending Tumor Lineage across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases. Clin Cancer Res 24(9):2182-2193, 2018. e-Pub 2018. PMID: 29440175.
146. Tan X, Banerjee P, Liu X, Yu J, Gibbons DL, Wu P, Scott KL, Diao L, Zheng X, Wang J, Jalali A, Suraokar M, Fujimoto J, Behrens C, Liu X, Liu CG, Creighton CJ, Wistuba II, Kurie JM. The Epithelial-to-Mesenchymal Transition Activator ZEB1 Initiates a Prometastatic Competing Endogenous RNA Network. J Clin Invest 128(4):1267-1282, 2018. e-Pub 2018. PMID: 29324442.
147. Gibbons DL, Creighton CJ. Pan-cancer Survey of Epithelial-Mesenchymal Transition Markers across the Cancer Genome Atlas. Dev Dyn 247(3):555-564, 2018. e-Pub 2018. PMID: 28073171.
148. Yamauchi M, Barker TH, Gibbons DL, Kurie JM. The Fibrotic Tumor Stroma. J Clin Invest 128(1):16-25, 2018. e-Pub 2018. PMID: 29293090.
149. Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ, Emerson R, Zhang J, Tipton C, Li J, Quek K, Gopalakrishnan V, Chen R, Vence LM, Cascone T, Vignali M, Fujimoto J, Rodriguez-Canales J, Parra ER, Little LD, Gumbs C, Forget MA, Federico L, Haymaker C, Behrens C, Benzeno S, Bernatchez C, Sepesi B, Gibbons DL, Wargo JA, William WN, Swisher S, Heymach JV, Robins H, Lee JJ, Sharma P, Allison JP, Futreal PA, Wistuba II, Zhang J. TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: an Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov 7(10):1088-1097, 2017. e-Pub 2017. PMID: 28733428.
150. Wei Y, Kim TJ, Peng DH, Duan D, Gibbons DL, Yamauchi M, Jackson JR, Le Saux CJ, Calhoun C, Peters J, Derynck R, Backes BJ, Chapman HA. Fibroblast-specific Inhibition of TGF- β1 Signaling Attenuates Lung and Tumor Fibrosis. J Clin Invest 127(10):3675-3688, 2017. e-Pub 2017. PMID: 28872461.
151. Chen F, Zhang Y, Bossé D, Lalani AA, Hakimi AA, Hsieh JJ, Choueiri TK, Gibbons DL, Ittmann M, Creighton CJ. Pan-urologic Cancer Genomic Subtypes that Transcend Tissue of Origin. Nat Commun 8(1):199, 2017. e-Pub 2017. PMID: 28775315.
152. Sen T, Tong P, Stewart CA, Cristea S, Valliani A, Shames DS, Redwood AB, Fan YH, Li L, Glisson BS, Minna JD, Sage J, Gibbons DL, Piwnica-Worms H, Heymach JV, Wang J, Byers LA. CHK1 Inhibition in Small Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. Cancer Res 77(14):3870-3884, 2017. e-Pub 2017. PMID: 28490518.
153. Sepesi B, Cuentes EP, Canales JR, Behrens C, Correa A, Antonoff M, Gibbons DL, Heymach J, Hofstetter W, Mehran R, Rice DC, Roth J, Vaporciyan AA, Walsh G, Weissferdt A, Kalhor N, Moran C, Swisher SG, Wistuba I. Tumor-Infiltrating Lymphocytes and Overall Survival in Surgically Resected Stage II and III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 98(1):223, 2017. e-Pub 2017. PMID: 28586974.
154. Stewart A, Tong P, Cardnell RJ, Sen T, Li L, Gay CM, Masrorpour F, Fan Y, Bara RO, Feng Y, Ru Y, Fujimoto J, Kundu ST, Post LE, Yu K, Shen Y, Glisson BS, Wistuba I, Heymach JV, Gibbons DL, Wang J, Byers LA. Dynamic Variations in Epithelial-to-Mesenchymal Transition (EMT), ATM, and SLFN11 Govern Response to PARP Inhibitors and Cisplatin in Small Cell Lung Cancer. Oncotarget 8(17):28575-28587, 2017. e-Pub 2017. PMID: 28212573.
155. Peng DH, Ungewiss C, Tong P, Byers LA, Wang J, Canales JR, Villalobos PA, Uraoka N, Mino B, Behrens C, Wistuba II, Han RI, Wanna CA, Fahrenholtz M, Grande-Allen KJ, Creighton CJ, Gibbons DL. Zeb1 Induces LOXL2-Mediated Collagen Stabilization and Deposition in the Extracellular Matrix to Drive Lung Cancer Invasion and Metastasis. Oncogene 36(14):1925-1938, 2017. e-Pub 2017. PMID: 27694892.
156. Peters HL, Tripathi SC, Kerros C, Katayama H, Garber HR, St John LS, Federico L, Meraz IM, Roth JA, Sepesi B, Majidi M, Ruisaard K, Clise-Dwyer K, Roszik J, Gibbons DL, Heymach JV, Swisher SG, Bernatchez C, Alatrash G, Hanash S, Molldrem JJ. Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. Cancer Immunol Res 5(4):319-329, 2017. e-Pub 2017. PMID: 28254787.
157. Chen F, Zhang Y, Parra E, Rodriguez J, Behrens C, Akbani R, Lu Y, Kurie JM, Gibbons DL, Mills GB, Wistuba II, Creighton CJ. Multiplatform-based Molecular Subtypes of Non-Small Cell Lung Cancer. Oncogene 36(10):1384-1393, 2017. e-Pub 2017. PMID: 27775076.
158. Choi M, Kadara H, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Kim K, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Herbst RS, Wistuba II. Mutation Profiles in Early-Stage Lung Squamous Cell Carcinoma with Clinical Follow-Up and Correlation with Markers of Immune Function. Ann Oncol 28(1):83-89, 2017. e-Pub 2017. PMID: 28177435.
159. Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS. Whole-Exome Sequencing and Immune Profiling of Early-Stage Lung Adenocarcinoma with Fully Annotated Clinical Follow-Up. Ann Oncol 28(1):75-82, 2017. e-Pub 2017. PMID: 27687306.
160. Yan X, Wang L, Zhang R, Pu X, Wu S, Yu L, Meraz IM, Zhang X, Wang JF, Gibbons DL, Mehran RJ, Swisher SG, Roth JA, Fang B. Overcoming Resistance to Anti-PD Immunotherapy in a Syngeneic Mouse Lung Cancer Model Using Locoregional Virotherapy. Oncoimmunology 7(1):e1376156, 2017. e-Pub 2017. PMID: 29296537.
161. Parra ER, Behrens C, Rodriguez-Canales J, Lin H, Mino B, Blando J, Zhang J, Gibbons DL, Heymach JV, Sepesi B, Swisher SG, Weissferdt A, Kalhor N, Izzo J, Kadara H, Moran C, Lee JJ, Wistuba II. Image Analysis-Based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-Small Cell Lung Carcinoma Patients. Clin Cancer Res 22(24):6278-6289, 2016. e-Pub 2016. PMID: 27252415.
162. Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV. Local Consolidative Therapy Versus Maintenance Therapy or Observation for Patients with Oligometastatic Non-Small-Cell Lung Cancer without Progression after First-Line Systemic Therapy: A Multicentre, Randomised, Controlled, Phase 2 Study. Lancet Oncol 17(12):1672-1682, 2016. e-Pub 2016. PMID: 27789196.
163. Tan X, Banerjee P, Guo HF, Ireland S, Pankova D, Ahn YH, Nikolaidis IM, Liu X, Zhao Y, Xue Y, Burns AR, Roybal J, Gibbons DL, Zal T, Creighton CJ, Ungar D, Wang Y, Kurie JM. Epithelial-to-Mesenchymal Transition Drives a Pro-Metastatic Golgi Compaction Process Through Scaffolding Protein PAQR11. J Clin Invest. e-Pub 2016. PMID: 27869652.
164. Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SE. Novel Algorithmic Approach Predicts Tumor Mutation Load and Correlates with Immunotherapy Clinical Outcomes Using a Defined Gene Mutation Set. BMC Med 14(1):168, 2016. e-Pub 2016. PMID: 27776519.
165. Choi M, Kadara H, Zhang J, Cuentas EP, Canales JR, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Kim K, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee JJ, Lifton RP, Herbst RS, Wistuba II. Mutation Profiles in Early-Stage Lung Squamous Cell Carcinoma with Clinical Follow-Up and Correlation with Markers of Immune Function. Ann Oncol. e-Pub 2016. PMID: 27687303.
166. Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, Goldberg SB, Tang X, Miller VA, Skoulidis F, Gibbons DL, Shen L, Wei C, Diao L, Peng SA, Wang J, Tam AL, Coombes KR, Koo JS, Mauro DJ, Rubin EH, Heymach JV, Hong WK, Herbst RS. The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients with Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. e-Pub 2016. PMID: 27480147.
167. Zhang T, Guo L, Creighton CJ, Lu Q, Gibbons DL, Yi ES, Deng B, Molina JR, Sun Z, Yang P, Yang Y. A Genetic Cell Context-Dependent Role for ZEB1 in Lung Cancer. Nat Commun 7:12231, 2016. e-Pub 2016. PMID: 27456471.
168. Lou Y, Diao L, Cuentas ER, Denning WL, Chen L, Fan YH, Byers LA, Wang J, Papadimitrakopoulou VA, Behrens C, Rodriguez JC, Hwu P, Wistuba II, Heymach JV, Gibbons DL. Epithelial-Mesenchymal Transition is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clin Cancer Res 22(14):3630-42, 2016. e-Pub 2016. PMID: 26851185.
169. Ferrarotto R, Goonatilake R, Young Yoo S, Tong P, Giri U, Peng S, Minna J, Girard L, Wang Y, Wang L, Li L, Diao L, Peng DH, Gibbons DL, Glisson BS, Heymach JV, Wang J, Byers LA, Johnson FM. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. Clin Cancer Res 22(7):1674-86, 2016. e-Pub 2016. PMID: 26597303.
170. Gibbons DL, Chow LQ, Kim DW, Kim SW, Yeh T, Song X, Jiang H, Taylor R, Karakunnel J, Creelan B. 57O Efficacy, Safety and Tolerability of MEDI4736 (Durvalumab [D]), A Human Igg1 Anti-Programmed Cell Death-Ligand-1 (PD-L1) Antibody, Combined with Gefitinib (G): A Phase I Expansion in TKI-Naïve Patients (Pts) with EGFR Mutant NSCLC. J Thorac Oncol 11(4 Suppl):S79, 2016. e-Pub 2016. PMID: 27198414.
171. Pankova D, Chen Y, Terajima M, Schliekelman MJ, Baird BN, Fahrenholtz M, Sun L, Gill BJ, Vadakkan TJ, Kim MP, Ahn YH, Roybal JD, Liu X, Parra Cuentas ER, Rodriguez J, Wistuba II, Creighton CJ, Gibbons DL, Hicks JM, Dickinson ME, West JL, Grande-Allen KJ, Hanash SM, Yamauchi M, Kurie JM. Cancer-Associated Fibroblasts Induce a Collagen Cross-Link Switch in Tumor Stroma. Mol Cancer Res 14(3):287-95, 2016. e-Pub 2016. PMID: 26631572.
172. Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, Skoulidis F, Parra ER, Rodriguez-Canales J, Wistuba II, Heymach JV, Weinstein JN, Coombes KR, Wang J, Byers LA. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial to Mesenchymal Transition. Clin Cancer Res 22(3):609-20, 2016. e-Pub 2016. PMID: 26420858.
173. Kundu ST, Byers LA, Peng DH, Roybal JD, Diao L, Wang J, Tong P, Creighton CJ, Gibbons DL. The Mir-200 Family and the Mir-183~96~182 Cluster Target Foxf2 to Inhibit Invasion and Metastasis in Lung Cancers. Oncogene 35(2):1-14, 2016. e-Pub 2016. PMID: 25798833.
174. Albritton JL, Roybal JD, Paulsen SJ, Calafat NJ, Flores-Zaher JA, Farach-Carson MC, Gibbons DL, Miller JS. Ultrahigh-Throughput Generation and Characterization of Cellular Aggregates in Laser-Ablated Microwells of Poly(Dimethylsiloxane). RSC Advances 6(11):8980-8991, 2016. e-Pub 2016.
175. Ungewiss C, Rizvi ZH, Roybal JD, Peng DH, Gold KA, Shin DH, Creighton CJ, Gibbons DL. The MicroRNA-200/Zeb1 Axis Regulates ECM-Dependent Β1-Integrin/FAK Signaling, Cancer Cell Invasion and Metastasis through CRKL. Sci Rep 6:18652, 2016. e-Pub 2016. PMID: 26728244.
176. Chen L, Yi X, Goswami S, Ahn YH, Roybal JD, Yang Y, Diao L, Peng D, Peng D, Fradette JJ, Wang J, Byers LA, Kurie JM, Ullrich SE, Qin FX, Gibbons DL. Growth and Metastasis of Lung Adenocarcinoma is Potentiated by BMP4-Mediated Immunosuppression. Oncoimmunology 5(11):e1234570, 2016. e-Pub 2016. PMID: 27999749.
177. Chen L, Heymach JV, Qin FX, Gibbons DL. The Mutually Regulatory Loop of Epithelial-Mesenchymal Transition and Immunosuppression in Cancer Progression. Oncoimmunology 4(5):e1002731, 2015. e-Pub 2015. PMID: 26155392.
178. Gibbons DL, Byers LA. A HER 1-2 Punch: Dual EGFR Targeting Deals Resistance a Deadly Blow. Cancer Discov 4(9):991-4, 2014. e-Pub 2014. PMID: 25185188.
179. Yang Y, Ahn YH, Chen Y, Tan X, Guo L, Gibbons DL, Ungewiss C, Peng DH, Liu X, Lin SH, Thilaganathan N, Wistuba II, Rodriguez-Canales J, McLendon G, Creighton CJ, Kurie JM. ZEB1 Sensitizes Lung Adenocarcinoma to Metastasis Suppression by PI3K Antagonism. J Clin Invest 124(6):2696-708, 2014. e-Pub 2014. PMID: 24762440.
180. Gibbons DL, Pricl S, Posocco P, Laurini E, Fermeglia M, Sun H, Talpaz M, Donato N, Quintás-Cardama A. Molecular Dynamics Reveal BCR-ABL1 Polymutants as a Unique Mechanism of Resistance to PAN-BCR-ABL1 Kinase Inhibitor Therapy. Proc Natl Acad Sci U S A 111(9):3550-5, 2014. e-Pub 2014. PMID: 24550512.
181. Mishra DK, Creighton CJ, Zhang Y, Gibbons DL, Kurie JM, Kim MP. Gene Expression Profile of A549 Cells from Tissue of 4D Model Predicts Poor Prognosis in Lung Cancer Patients. Int J Cancer 134(4):789-98, 2014. e-Pub 2014. PMID: 23934967.
182. Gibbons DL, Byers LA, Kurie JM. Smoking, p53 Mutation, and Lung Cancer. Mol Cancer Res 12(1):3-13, 2014. e-Pub 2014. PMID: 24442106.
183. Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, Diao L, Wang J, Roybal JD, Patel M, Ungewiss C, Peng D, Antonia S, Mediavilla-Varela M, Robertson G, Jones S, Suraokar M, Welsh JW, Erez B, Wistuba II, Chen L, Peng D, Wang S, Ullrich SE, Heymach JV, Kurie JM, Qin FX. Metastasis is Regulated via Microrna-200/ZEB1 Axis Control of Tumour Cell PD-L1 Expression and Intratumoral Immunosuppression. Nat Commun 5:5241, 2014. e-Pub 2014. PMID: 25348003.
184. Laurini E, Posocco P, Fermeglia M, Gibbons DL, Quintás-Cardama A, Pricl S. Through the Open Door: Preferential Binding of Dasatinib to the Active Form of BCR-ABL Unveiled by in Silico Experiments. Mol Oncol 7(5):968-75, 2013. e-Pub 2013. PMID: 23816609.
185. Liu Y, Marks K, Cowley GS, Carretero J, Liu Q, Nieland TJ, Xu C, Cohoon TJ, Gao P, Zhang Y, Chen Z, Altabef AB, Tchaicha JH, Wang X, Choe S, Driggers EM, Zhang J, Bailey ST, Sharpless NE, Hayes DN, Patel NM, Janne PA, Bardeesy N, Engelman JA, Manning BD, Shaw RJ, Asara JM, Scully R, Kimmelman A, Byers LA, Gibbons DL, Wistuba II, Heymach JV, Kwiatkowski DJ, Kim WY, Kung AL, Gray NS, Root DE, Cantley LC, Wong KK. Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a Target in LKB1 Mutant Lung Cancer. Cancer Discov 3(8):870-9, 2013. e-Pub 2013. PMID: 23715154.
186. Baird BN, Schliekelman MJ, Ahn YH, Chen Y, Roybal JD, Gill BJ, Mishra DK, Erez B, O'Reilly M, Yang Y, Patel M, Liu X, Thilaganathan N, Larina IV, Dickinson ME, West JL, Gibbons DL, Liu DD, Kim MP, Hicks JM, Wistuba II, Hanash SM, Kurie JM. Fibulin-2 is a Driver of Malignant Progression in Lung Adenocarcinoma. PLoS One 8(6):e67054, 2013. e-Pub 2013. PMID: 23785517.
187. Creighton CJ, Gibbons DL, Kurie JM. The Role of Epithelial-Mesenchymal Transition Programming in Invasion and Metastasis: A Clinical Perspective. Cancer Manag Res 5:187-95, 2013. e-Pub 2013. PMID: 23986650.
188. Gill BJ, Gibbons DL, Roudsari LC, Saik JE, Rizvi ZH, Roybal JD, Kurie JM, JL† W. A Synthetic Matrix with Independently Tunable Biochemistry and Mechanical Properties to Study Epithelial Morphogenesis and EMT in a Lung Adenocarcinoma Model. Cancer Res 72(22):6013-23, 2012. e-Pub 2012. PMID: 22952217.
189. Ahn YH, Gibbons DL, Chakravarti D, Creighton CJ, Rizvi ZH, Adams HP, Pertsemlidis A, Gregory PA, Wright JA, Goodall GJ, Flores ER, Kurie JM. ZEB1 Drives Prometastatic Actin Skeletal Remodeling by Downregulating miR-34a Expression. J Clin Invest 122(9):3170-83, 2012. e-Pub 2012. PMID: 22850877.
190. Gibbons DL, Pricl S, Kantarjian H, Cortes J, Quintás-Cardama A. The Rise and Fall of Gatekeeper Mutations? The BCR-ABL1 T315I Paradigm. Cancer 118(2):293-9, 2012. e-Pub 2012. PMID: 21732333.
191. Chatterjee S, Seifried L, Feigin ME, Gibbons DL, Scuoppo C, Lin W, Rizvi ZH, Lind E, Dissanayake D, Kurie JM, Ohashi P, Muthuswamy SK. Dysregulation of Cell Polarity Proteins Synergize with Oncogenes or the Microenvironment to Induce Invasive Behavior in Epithelial Cells. PLoS One 7(4):e34343, 2012. e-Pub 2012. PMID: 22529912.
192. Schliekelman MJ, Gibbons DL, Faca VM, Creighton CJ, Rizvi ZH, Zhang Q, Wong CH, Wang H, Ungewiss C, Ahn YH, Shin DH, Kurie JM, Hanash SM. Targets of the Tumor Suppressor miR-200 in Regulation of the Epithelial-mesenchymal Transition in Cancer. Cancer Res 71(24):7670-82, 2011. e-Pub 2011. PMID: 21987723.
193. Ahn YH, Yang Y, Gibbons DL, Creighton CJ, Yang F, Wistuba II, Lin W, Thilaganathan N, Alvarez CA, Roybal J, Goldsmith EJ, Tournier C, Kurie JM. Map2k4 Functions as a Tumor Suppressor in Lung Adenocarcinoma and Inhibits Tumor Cell Invasion by Decreasing PPAR{gamma}2. Mol Cell Biol 31(21):4270-85, 2011. e-Pub 2011. PMID: 21896780.
194. Yang Y, Ahn YH, Gibbons DL, Zang Y, Lin W, Thilaganathan N, Alvarez CA, Moreira DC, Creighton CJ, Gregory PA, Goodall GJ, Kurie JM. The Notch Ligand Jagged 2 Promotes Tumor Metastasis by Activating a Double-negative Feedback Loop Involving GATA3 and MicroRNA-200. J Clin Invest 121(4):1373-85, 2011. e-Pub 2011. PMID: 21403400.
195. Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A. Treatment of Non-small-cell Lung Cancer with Erlotinib or Gefitinib. N Engl J Med 364(10):947-55, 2011. e-Pub 2011. PMID: 21388312.
196. Roybal JD, Zang Y, Ahn YH, Yang Y, Gibbons DL, Baird BN, Alvarez C, Thilaganathan N, Liu DD, Saintigny P, Heymach JV, Creighton CJ, Kurie JM. miR-200 Inhibits Lung Adenocarcinoma Cell Invasion and Metastasis by Targeting Flt1/VEGFR1. Mol Cancer Res 9(1):25-35, 2011. e-Pub 2011. PMID: 21115742.
197. Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, Thilaganathan N, Du L, Zhang Y, Pertsemlidis A, Kurie JM. Contextual Extracellular Cues Promote Tumor Cell EMT and Metastasis by Regulating miR-200 Family Expression. Genes Dev 23(18):2140-51, 2009. e-Pub 2009. PMID: 19759262.
198. Choi K, Ahn YH, Gibbons DL, Tran HT, Creighton CJ, Girard L, Minna JD, Qin FX, Kurie JM. Distinct Biological Roles for the Notch Ligands Jagged-1 and Jagged-2. J Biol Chem 284(26):17766-74, 2009. e-Pub 2009. PMID: 19398556.
199. Gibbons DL, Lin W, Creighton CJ, Zheng S, Berel D, Yang Y, Raso MG, Liu DD, Wistuba II, Lozano G, Kurie JM. Expression Signatures of Metastatic Capacity in a Genetic Mouse Model of Lung Adenocarcinoma. PLoS One 4(4):e5401, 2009. e-Pub 2009. PMID: 19404390.
200. Quintás-Cardama A, Gibbons DL, Cortes J, Bobadilla D, Slovak ML, Kantarjian H, Abruzzo LV. Association of 3q21q26 Syndrome and Late-appearing Philadelphia Chromosome in Acute Myeloid Leukemia. Leukemia 22(4):877, 2008. e-Pub 2008. PMID: 17928880.
201. Quintás-Cardama A, Gibbons DL, Kantarjian H, Talpaz M, Donato N, Cortes J. Sequencing of Subcloned PCR Products Facilitates Earlier Detection of BCR-ABL1(T315I) and Other Mmutants Compared to Direct Sequencing of the ABL1 Kinase Domain. Leukemia 22(4):885, 2008. e-Pub 2008. PMID: 18305550.
202. Gibbons DL, Ahn A, Liao M, Hammar L, Cheng RH, Kielian M. Multistep Regulation of Membrane Insertion of the Fusion Peptide of Semliki Forest Virus. J Virol 78(7):3312-8, 2004. e-Pub 2004. PMID: 15016852.
203. Gibbons DL, Reilly B, Ahn A, Vaney MC, Vigouroux A, Rey FA, Kielian M. Purification and Crystallization Reveal Two Types of Interactions of the Fusion Protein Homotrimer of Semliki Forest Virus. J Virol 78(7):3514-23, 2004. e-Pub 2004. PMID: 15016874.
204. Gibbons DL, Vaney MC, Roussel A, Vigouroux A, Reilly B, Lepault J, Kielian M, Rey FA. Conformational Change and Protein-protein Interactions of the Fusion Protein of Semliki Forest Virus. Nature 427(6972):320-5, 2004. e-Pub 2004. PMID: 14737160.
205. Gibbons DL, Erk I, Reilly B, Navaza J, Kielian M, Rey FA, Lepault J. Visualization of the Target-membrane-inserted Fusion Protein of Semliki Forest virus by Combined Electron Microscopy and Crystallography. Cell 114(5):573-83, 2003. e-Pub 2003. PMID: 13678581.
206. Ahn A, Gibbons DL, Kielian M. The Fusion Peptide of Semliki Forest virus Associates with Sterol-rich Membrane Domains. J Virol 76(7):3267-75, 2002. e-Pub 2002. PMID: 11884551.
207. Gibbons DL, Kielian M. Molecular Dissection of the Semliki Forest virus Homotrimer Reveals Two Functionally Distinct Regions of the Fusion Protein. J Virol 76(3):1194-205, 2002. e-Pub 2002. PMID: 11773395.
208. Gibbons DL, Ahn A, Chatterjee PK, Kielian M. Formation and Characterization of the Trimeric form of the Fusion Protein of Semliki Forest Virus. J Virol 74(17):7772-7780, 2000. e-Pub 2000. PMID: 10933683.
209. Gibbons DL, Hixson JD, Hay N, Lund P, Gorovits BM, Ybarra J, Horowitz PM. Intrinsic Fluorescence Studies of the Chaperonin GroEL Containing Single Tyr --> Trp Replacements Reveal Ligand-induced Conformational Changes. J Biol Chem 271(50):31989-95, 1996. e-Pub 1996. PMID: 8943246.
210. Gibbons DL, Horowitz PM. Ligand-induced Conformational Changes in the Apical Domain of the Chaperonin GroEL. J Biol Chem 271(1):238-43, 1996. e-Pub 1996. PMID: 8550566.
211. Arystarkhova E, Gibbons DL, Sweadner KJ. Topology of the Na, K-ATPase. Evidence for Externalization of a Labile Transmembrane Structure during Heating. J Biol Chem 270(15):8785-8796, 1995. e-Pub 1995. PMID: 7721785.
212. Gibbons DL, Horowitz PM. Exposure of Hydrophobic Surfaces on the Chaperonin GroEL Oligomer by Protonation or Modification of His-401. J Biol Chem 270(13):7335-7340, 1995. e-Pub 1995. PMID: 7706275.
213. Horowitz PM, Hua S, Gibbons DL. Hydrophobic Surfaces that are Hidden in Chaperonin Cpn60 can be Exposed by Formation of Assembly-Competent Monomers or by Ionic perturbation of the Oligomer. J Biol Chem 270(4):1535-1542, 1995. e-Pub 1995. PMID: 7829481.
214. Sweadner KJ, Herrera VL, Amato S, Moellmann A, Gibbons DL, Repke KR. Immunologic Identification of Na+,K(+)-ATPase Isoforms in Myocardium. Isoform Change in Deoxycorticosterone Acetate-salt Hypertension. Circ Res 74(4):669-78, 1994. e-Pub 1994. PMID: 8137503.

Review Articles

1. Xia Y, Wang K, Zhao J, Arter Z, Zhang Y, Zhou J, Lu Y, Zeng L, Du R, Owens JA, Elamin YY, Gay CM, Skoulidis F, Tsao AS, Lu C, Cascone T, Gibbons DL, Zhang J, Chen O, Mok KKS, Nagasaka M, Li W, Heymach JV, Ignatius Ou SH, Li M, Le X. Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review. J Thorac Oncol 20(4):465-474, 2025. e-Pub 2025. PMID: 39622411.
2. Miao, S, Rodriguez, B, Gibbons, DL. The Multifaceted Role of Neutrophils in NSCLC in the Era of Immune Checkpoint Inhibitors. Cancers 16(14), 2024. e-Pub 2024. PMID: 39061147.
3. Konen, JM, Wu, H, Gibbons, DL. Immune checkpoint blockade resistance in lung cancer. Trends in Pharmacological Sciences 45(6):520-536, 2024. e-Pub 2024. PMID: 38744552.
4. Bajaj R, Warner AN, Fradette JF, Gibbons DL. Dance of The Golgi: Understanding Golgi Dynamics in Cancer Metastasis. Cells 11(9), 2022. e-Pub 2022. PMID: 35563790.
5. Perez-Oquendo M, Gibbons DL. Regulation of ZEB1 Function and Molecular Associations in Tumor Progression and Metastasis. Cancers (Basel) 14(8), 2022. e-Pub 2022. PMID: 35454770.
6. Weissferdt A, Pataer A, Swisher SG, Heymach JV, Gibbons DL, Cascone T, Sepesi B. Controversies and Challenges in the Pathologic Examination of Lung Resection Specimens after Neoadjuvant Treatment. Lung Cancer 154:76-83, 2021. e-Pub 2021. PMID: 33631448.
7. Pradhan M, Chocry M, Gibbons DL, Sepesi B, Cascone T. Emerging Biomarkers for Neoadjuvant Immune Checkpoint Inhibitors in Operable Non-small Cell Lung Cancer. Transl Lung Cancer Res 10(1):590-606, 2021. e-Pub 2021. PMID: 33569339.
8. Konen JM, Fradette JJ, Gibbons DL. The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid Tumors. Cells 9(1), 2019. e-Pub 2019. PMID: 31878283.
9. Soundararajan R, Fradette JJ, Konen JM, Moulder S, Zhang X, Gibbons DL, Varadarajan N, Wistuba II, Tripathy D, Bernatchez C, Byers LA, Chang JT, Contreras A, Lim B, Parra ER, Roarty EB, Wang J, Yang F, Barton M, Rosen JM, Mani SA. Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. Cancers (Basel) 11(5), 2019. e-Pub 2019. PMID: 31137625.
10. Kielian M, Chatterjee PK, Gibbons DL, Lu YE. Specific Roles for Lipids in Virus Fusion and Exit: Examples from the Alphaviruses. Subcell Biochem 34:409-455, 2000. e-Pub 2000. PMID: 10808340.

Other Articles

1. Rahal Z, Liu Y, Peng F, Yang S, Jamal MA, Sharma M, Moreno H, Damania AV, Wong MC, Ross MC, Sinjab A, Zhou T, Chen M, Reischle IT, Feng J, Chukwuocha C, Tang E, Abaya C, Lim JK, Leung CH, Lin HY, Deboever N, Lee JJ, Sepesi B, Gibbons DL, Wargo JA, Fujimoto J, Wang L, Petrosino JF, Ajami NJ, Jenq RR, Moghaddam SJ, Cascone T, Hoffman K, Kadara H Correction: Inflammation Mediated by Gut Microbiome Promotes Immune Suppression and Lung Adenocarcinoma Progression. Cancer Immunol Res 13(10):1687, 2025. PMID: 40920201.
2. Skoulidis, F, Araujo, HA, Do, MT, Qian, Y, Sun, X, Cobo, AG, Le, JT, Montesion, M, Palmer, R, Jahchan, NS, Juan, J, Min, C, Yu, Y, Pan, X, Arbour, KC, Vokes, N, Schmidt, S, Molkentine, D, Owen, D, Memmott, R, Patil, P, Marmarelis, ME, Awad, MM, Murray, J, Hellyer, JA, Gainor, J, Dimou, A, Bestvina, CM, Shu, CA, Riess, JW, Blakely, CM, Pecot, CV, Mezquita, L, Tabbò, F, Scheffler, M, Digumarthy, S, Mooradian, MJ, Sacher, A, Lau, SC, Saltos, A, Rotow, JK, Johnson, RP, Liu, C, Stewart, TF, Goldberg, SB, Killam, J, Walther, Z, Schalper, K, Davies, KD, Woodcock, MG, Anagnostou, V, Marrone, KA, Forde, PM, Ricciuti, B, Venkatraman, D, Van Allen, EM, Cummings, AL, Goldman, JW, Shaish, H, Kier, M, Katz, S, Aggarwal, C, Ni, Y, Azok, J, Segal, J, Ritterhouse, LL, Neal, JW, Lacroix, L, Elamin, YY, Vailati Negrao, M, Le, X, Lam, VK, Lewis, WE, Kemp, HN, Carter, B, Roth, JA, Swisher, S, Lee, R, Zhou, T, Poteete, A, Kong, Y, Takehara, T, Paula, AG, Parra Cuentas, ER, Behrens, MC, Wistuba, II, Zhang, J, Blumenschein, GR, Gay, CM, Byers, LA, Gibbons, DL, Tsao, A, Lee, JJ, Bivona, T, Camidge, DR, Gray, JE, Leighl, NB, Levy, BP, Brahmer, JR, Garassino, MC, Gandara, D, Garon, EB, Rizvi, NA, Scagliotti, G, Wolf, J, Planchard, D, Besse, B, Herbst, RS, Wakelee, HA, Pennell, N, Shaw, AT, Jänne, PA, Carbone, DP, Hellmann, MD, Rudin, CM, Albacker, LA, Mann, H, Zhu, Z, Lai, Z, Stewart, RA, Peters, S, Johnson, M, Wong, KK, Huang, A, Winslow, MM, Rosen, MJ, Winters, IP, Papadimitrakopoulou, VA, Cascone, T, Jewsbury, P, Heymach, JV Correction to. Nature 639(8054):E19, 2025. PMID: 40016449.
3. Kim, ST, Chu, Y, Misoi, MW, Suarez-Almazor, M, Tayar, JH, Lu, H, Buni, M, Kramer, J, Rodriguez, E, Hussain, Z, Neelapu, SS, Wang, RJ, Shah, AY, Tannir, NM, Campbell, M, Gibbons, DL, Cascone, T, Lu, C, Blumenschein, GR, Altan, M, Lim, B, Valero, V, Loghin, ME, Tu, J, Westin, SN, Naing, A, Garcia-Manero, G, Hassan, NA, Tawbi, H, Hwu, P, Oliva, IC, Davies, MA, Patel, SP, Zou, J, Futreal, A, Diab, A, Wang, L, Nurieva, R Author Correction. Nature communications 15(1), 2024. PMID: 38965214.
4. Nussinov, R, Weichhart, T, Dlamini, Z, Gibbons, DL, Van Seuningen, I, Konen, JM, Ju, H Directions to overcome therapy resistance in cancer. Trends in Pharmacological Sciences 45(6):467-471, 2024. PMID: 38760267.
5. Sun, H, Cao, S, Mashl, RJ, Mo, CK, Zaccaria, S, Wendl, MC, Davies, S, Bailey, MH, Primeau, T, Hoog, J, Mudd, JL, Dean, DA, Patidar, R, Chen, L, Wyczalkowski, MA, Jayasinghe, R, Rodrigues, FM, Terekhanova, NV, Li, Y, Lim, KH, Wang-Gillam, A, Van Tine, BA, Ma, C, Aft, R, Fuh, KC, Schwarz, JK, Roth, JA, Tapia, C, Yang, F, Akcakanat, A, Chen, H, Dai, B, Gibbons, DL, Ha, MJ, Jensen, VB, Kim, M, Kopetz, S, Menter, DG, Meraz, I, Sorokin, A, Wang, J, Westin, SN, Xi, Y, Yap, TA, Yennu Nanda, VG, Zhang, X, Zheng, X, Davies, MA, Fang, B, Meric-Bernstam, F Author Correction. Nature communications 13(1), 2022. PMID: 34996889.
6. Woo, XY, Giordano, J, Srivastava, A, Zhao, ZM, Lloyd, M, de Bruijn, R, Suh, YS, Patidar, R, Chen, L, Scherer, S, Bailey, M, Yang, CH, Cortes-Sanchez, E, Xi, Y, Wang, J, Wickramasinghe, JM, Kossenkov, AV, Rebecca, VW, Sun, H, Mashl, RJ, Davies, S, Jeon, R, Frech, C, Randjelovic, J, Rosains, J, Galimi, F, Bertotti, A, Lafferty, A, O’Farrell, AC, Modave, E, Fang, B, Roth, JA, Meric-Bernstam, F, Davies, MA, Zheng, X, Zhang, X, Akcakanat, A, Yap, TA, Ha, MJ, Chen, H, Kopetz, S, Menter, DG, Westin, SN, Kim, M, Dai, B, Gibbons, DL, Tapia, C, Jensen, VB, Yennu Nanda, VG, Mælandsmo, GM Author Correction. Nature Genetics 53(5):761, 2021. PMID: 33608693.

Abstracts

1. Daniel Boiarsky, Lingzhi Hong, Alissa Jamie Cooper, Biagio Ricciuti, Maliazurina B. Saad, Arielle Elkrief, Alessandro Di Federico, Muhammad Aminu, Waree Rinsurongkawong, Jeff Lewis, Gibbons DL, Ara A. Vaporciyan, Xiuning Le, J. Jack Lee, John Heymach, Jia Wu, Mark M. Awad, Adam Jacob Schoenfeld, Jianjun Zhang, Natalie I Vokes. Molecular profiling of metastatic lung squamous cell carcinoma (mLUSC) to identify patients with differential response to immune checkpoint inhibitor (ICI) therapy. 2025 ASCO Annual Meeting, Chicago, Illinois, 2025. e-Pub 2025.
2. Nirosha D. Perera,, Lingzhi Hong, Waree Rinsurongkawong, Elliana Young, Dawen Sui, Lorna H McNeill, Vadeerat Rinsurongkawong, Jeff Lewis, J. Jack Lee, Mehmet Altan, Bingnan Zhang, Xiuning Le, Hai T. Tran, Haniel Alves Araujo, Gibbons DL, Ara A. Vaporciyan, John Heymach, Jianjun Zhang, John Kent Lin. Race-associated clinicogenomic correlates of outcomes to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer (NSCLC). 2025 ASCO Annual Meeting, 2025. e-Pub 2025.
3. Adam Grippin, Christiano Marconi, Sage Copling, Priti Gupta, Elliana Young, Padmanee Sharma, Gibbons DL, Hai Tran, Yon Son Betty Kim, Jianjun Zhang, Jennifer Wargo, John V. Heymach, Hector Mendez-Gomez, Wen Jiang, Elias Sayour, Steven H. Lin. SARS-CoV-2 mRNA vaccines sensitize tumors to immune checkpoint blockade. 2025 AACR Annual Meeting, 2025. e-Pub 2025.
4. Morris BB, Zhang Z, Lynch AR, Heeke S, Concannon K, Stewart C, Wang R, Halliday A, Rinsurongkawong W, Rinsurongkawong V, Lee J, Zhang J, Gibbons DL, Vaporciyan AA, Gay CM, Tran HT, Heymach JV, Byers LA, Loo PV. Reconstructing small cell lung cancer evolution using deep whole genome sequencing of circulating tumor DNA Available. 2025 AACR Annual Meeting, 2025. e-Pub 2025.
5. Rahal Z, Zhou T, Serrano AG, Feng J, Vaccaro A, Sinjab A, Le JT, Sun X, Wang M, Hu W, Zhang J, Bruno T, Tran H, Swisher SG, Leung CH, Lee J, Wang J, Heymach JV, Gibbons DL, Wistuba II, Weissferdt A, Burks JK, Solis Soto LM, Kadara H, Cascone T. Spatial and cellular immune landscapes of non-small cell lung cancer in association with response to neoadjuvant chemoimmunotherapy. 2025 AACR Annual Meeting, 2025. e-Pub 2025.
6. Hong Chen, Bo Zhu, Junya Fujimoto, Jian-Rong Li, Chenyang Li, Pingjun Chen, Alexandre Reuben, Monique Nilsson, Xiuning Le, Alissa Poteete, Shawna M. Hubert, Gibbons DL, Ignacio I. Wistuba, Jia Wu, Chao Cheng, John V. Heymach, Jianjun Zhang. Dynamic crosstalk between endothelial and epithelial cells drives tumor progression in lung adenocarcinoma. 2025 AACR Annual Meeting, 2025. e-Pub 2025.
7. Elamin YY, Gandhi S, Saad M, Rehmani S, Antonoff MB, Gibbons DL, Le X, Negrao MV, Lam V, Byers L, Cascone T, Blumenschein G, Chang J, Vaporciyan A, Liao Z, Swisher S, Yin J, Zhang P, Wu J, Heymach JV. BRIGHTSTAR: A phase II trial of local consolidative therapy (LCT) with brigatinib in tyrosine kinase inhibitor (TKI)-naïve ALK-rearranged oligo- and poly-metastatic NSCLC. 2023 ASCO Annual Meeting, 2023. e-Pub 2023.
8. Heeke S, Gandhi S, Tran HT, Lam V, Byers LA, Gibbons DL, Gay CM, Altan M, Antonoff MB, Le X, Tu J, Pek M, Poh J, Ngew KC, Tsao A, Cascone T, Negrao M, Jr BG, Heymach JV, Elamin YY. Longitudinal tracking of ALK-positive lung cancer from plasma using circulating-tumor RNA and circulating-tumor DNA in the BRIGHTSTAR clinical trial. 2023 ASCO Annual Meeting, 2023. e-Pub 2023.
9. Stewart CA, Diao L, Xi Y, Wang R, Ramkumar K, Rodriguez BL, Morris BB, Shen L, Zhang B, Yang Y, Tanimoto A, Novegil VY, Soto LS, Rocha PD, Vokes N, Gibbons D, Frumovitz M, Fujimoto J, Wang J, Glisson B, LA Byers LA, CM Gay CM. YAP1 in relapsed pulmonary high-grade neuroendocrine carcinomas (NEC) is associated with CDKN2A loss, intact RB1, EMT and therapeutic vulnerability to MEK1 and CDK4/6 inhibition. AACR Annual Meeting 2023, 2023. e-Pub 2023.
10. Perez-Oquendo M, Manshouri R, Gibbons D. ZEB1 acetylation regulates dimerization and protein stability to promote lung adenocarcinoma progression and metastasis. 2022 AACR Annual Meeting, Chicago, Illinois, 2022. e-Pub 2022.
11. Kundu ST, Rodriguez BL, Gibson LA, Bajaj R, Perez MG, Fradette JJ, Class CA, Solis LM, Rojas Alvarez FR, Wistuba II, Diao L, Chen F, Sachdeva M, Wang J, Kirsh DG, Creighton CJ, Gibbons DL. MicroRNA-183/96/182 Cluster Inhibits Lung Cancer Progression and Metastasis by Inducing an Interleukin-2 Mediated Anti-tumor CD8+ CTL Response. 2021 Biology of Cancer: Microenvironment & Metastasis (Virtual), 2021. e-Pub 2021.
12. Bajaj R, Rodriguez BL, Gibbons DL. Targeting a Novel Pathway in Golgi Exocytosis to Enhance Anti-tumor Immune Response and Inhibit Metastatic NSCLC. 2021 Biology of Cancer: Microenvironment & Metastasis (Virtual), 2021. e-Pub 2021.
13. Perez-Oquendo M, Manshouri R, Gibbons DL. Regulation and Function of ZEB1 Dimerization in Lung Adenocarcinoma Progression and Metastasis. AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, 2021. e-Pub 2021.
14. Elamin Y, Gandhi S, Antonoff M, Mott F, Gibbons DL, Le X, Negrao MV, Sepesi B, Karam JA, Cascone T, Wang L, Blumenschein G, Glisson BS, Tsao AS, John Heymach J. BRIGHTSTAR: A pilot trial of local consolidative therapy (LCT) with brigatinib in tyrosine kinase inhibitor (TKI)-naïve ALK-rearranged advanced NSCLC. 2020 ASCO Virtual Scientific Program, 2020. e-Pub 2020.
15. Cascone T, Wi N, Weissferdt A, Lin HY, Hong Leung C, Carter BW, Fossella FV, Mott F, Papadimitrakopoulou V, Blumenschein Jr GR, Le X, Federico L, Roger Parra Cuentas E, Bernatchez C, Wistuba II, Vaporciyan AA, Gibbons DL, Swisher S, Heymach J, Sepesi B. NSCLC: Clinical and Correlative Results from the NEOSTAR Study. 2019 ASCO Annual Meeting, Chicago, Illinois, 2019. e-Pub 2019.
16. Reuben A, Zhang J, Lin HY, Little A, Gumbs C, Tran HT, Wang L, Haymaker CL, Mehran RJ, Rice DC, Walsh GL, Lee JJ, Wistuba II, Swisher S, Vaporciyan AA, Futreal A, Sepesi B, Heymach J, Gibbons DL, Cascone T. T Cell Repertoire Analysis of Non-Small Cell Lung Cancer Patients Treated with Neoadjuvant Nivolumab Alone or in Combination with Ipilimumab (NEOSTAR Trial). 2019 ASCO Annual Meeting, Chicago, Illinois, 2019. e-Pub 2019.
17. Hong L, Dibaj S, Negrao MV, Reuben A, Roarty E, Rinsurongkawong, Lewis J, Gibbons DL, Sepesi B, Papadimitrakopoulou V, Glisson BS, Blumenschein Jr GR, Futreal PA, Wistuba II, Roth JA, Swisher S, Heymach J, Simon GR, Lee JJ, Zhang J. Spatial and Temporal Heterogeneity of PD-L1 and its Impact on Benefit from Immune Checkpoint Blockade in Non-Small Cell Lung Cancer (NSCLC). 2019 ASCO Annual Meeting, Chicago, Illinois, 2019. e-Pub 2019.
18. Mitchell KG, Diao L, Tran HT, Negrao MV, Karpinets T, Wang J, Parra Cuentas ER, Corsini EM, Reuben A, Federico L, Bernatchez C, Vaporciyan AA, Swisher S, Cascone T, Wistuba II, Heymach J, Zhang J, Gibbons DL, Haymaker CL, Sepesi B. Association of Relative Neutrophilia with a Distinct Immunoinhibitory Milieu in Non-Small Cell Lung Cancer. 2019 ASCO Annual Meeting, Chicago, Illinois, 2019. e-Pub 2019.
19. Joseph R, Soundararajan R, Vasaikar S, Yang F, Isgandarova S, Tian L, Haemmerle M, Mino B, Zhou T, Vidhya Raja G, Ramirez Pena E, Den Hollander P, Bhangre N, Shin C, Martinez M, Rodriguez Canales J, Chang J, Sood A, Wistuba II, Gibbons DL, Rosen JM, Acharya G, Varadarajan N, Zhang XH, Mani SA. 3761 / 14 - Regulation of Metastasis by CD8 T Lymphocytes. 2019 AACR Annual Meeting, 2019. e-Pub 2019.
20. Le X, Negrao MV, Reuben A, Lee W, Parra E, Li J, Karpinets T, Behrens C, Sepesi B, Vaporiciyan A, Roth J, Haymaker C, Roarty E, Zhang J, Bernatchez C, Zhang J, Wistuba I, Gibbons DL, Heymach J. 5028 / 22 - Characterization of the Tumor Immune Microenvironment in Treatment-naïve EGFR-mutant NSCLC Uncovers a Low IFN-gamma Suppressive Immune Phenotype. 2019 AACR Annual Meeting, 2019. e-Pub 2019.
21. Negrao MV, Karpinets T, Li J, Reuben A, Haymaker C, Mitchell KG, Fujimoto F, Chow CW, Parra ER, Federico L, Zhang J, Vaporciyan AA, Bernatchez C, Cascone T, Sepesi B, Wistuba II, Heymach JV, Zhang J, Gibbons DL. 1176 / 3 - Immunogenomic Profiling Identifies a Subgroup of Squamous Cell Lung Cancers with Immunosuppressed Tumor Microenvironment and Correlates TGF-beta and Wnt/beta-catenin Signaling as Predictive of Low PD-L1 Expression. 2019 AACR Annual Meeting, 2019. e-Pub 2019.
22. Ramkumar K, Tong P, Fan HY, Peng D, Heymach JV, Gibbons DL, Wang J, Byers LA. 276 / 20 - Targeting AXL Sensitizes Non-Small Cell Lung Cancer to ATR Inhibitors by Enhancing Replication Stress. 2019 AACR Annual Meeting, 2019. e-Pub 2019.
23. Tang X, Lu W, Zhang J, Berhens C, Parra ER, Wineman J, Zhang J, Gibbons DL, Koeppel M, Kerns BJ, Stern M, Sepesi B, Lee JJ, Wistuba II. Gene Expression Difference (GED) Revealed Immune Function Gene Down-Regulation as Tumor-Associated Inflammatory Cell (TAIC) Infiltration in Microenvironment in Non-Small Cell Lung Cancer (NSCLC). AACR Annual Meeting 2018, Chicago, IL, 2018. e-Pub 2018.
24. Parra ER, Jiang M, Zhang J, Behrens C, Lee J, Heymach JV, Forget MA, Haymaker C, Bernatchez C, Moran C, Zhang J, Gibbons DL, Wistuba I. Immunofluorescence Profiling of Co-Expression of Multiple Immune Checkpoints in Malignant and Tumor Infiltrated Lymphocytes in Non-Small Cell Lung Carcinomas using Image Analysis System. AACR Annual Meeting 2018, Chicago, IL, 2018. e-Pub 2018.
25. Chen L, Li Y, Yi X, Gibbons DL. Targeting CD38 to Improve Anti-PD-1/CTLA-4 Combination Therapy in Lung Cancer. J Clin Oncol 36(suppl 5S), 2018. e-Pub 2018.
26. Chen L, Diao L, Yang Y, Yi X, Rodriguez J, Fan Y, Rodriguez L, Fradette J, Ungewiss C, Roybal J, Zhu J, Wang J, Byers LA, Ullrich S, Wistuba I, Heymach J, Qin XF, Gibbons DL. CD38 Blockade Overcomes the Immune Resistance to Anti-PD-L1 Therapy by Boosting CD8 T Cell Response. AACR Annual Meeting 2017, Washington, DC, 2017. e-Pub 2017.
27. Cuentas ER, Behrens C, Rodriguez-Canales J, Jiang M, Pataer A, Correa A, Swisher S, Sepesi B, Weissferdt A, Kalhor N, Zhang J, Lee J, Heymach J, Moran C, Zhang J, Gibbons DL, Wistuba. Neoadjuvant Chemotherapy Influence Changes of the Immune Response in Non-Small Cell Lung Carcinomas Immune Response in Non-Small Cell Lung Carcinomas. AACR Annual Meeting 2017, Washington, DC, 2017. e-Pub 2017.
28. Federico L, Haymaker C, Forget M, Vence L, Team I, Sharma P, Allison J, Fang B, Zhang J, Wagner H, Bogatenkova E, Wistuba I, Sepesi B, Heymach J, Gibbons DL, Bernatchez C. Phenotypic and Functional Profiling of Tumor-Infiltrating Lymphocytes (TIL) in Early Stage Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol:S325, 2017. e-Pub 2017.
29. Parra E, Rodriguez-Canales J, Behrens C, Jiang M, Pataer A, Correa A, Swisher S, Sepesi B, Weissferdt A, Kalhor N, William Jr W, Lee J, Heymach J, Moran C, Zhang J, Gibbons DL, Wistuba I. The Influence of Neoadjuvant Chemotherapy, on Immune Response Profile in Non-Small Cell Lung Carcinomas. J Thorac Oncol 12(S1):S164-S165, 2017. e-Pub 2017.
30. Behrens C, Parra E, Rodriguez-Canales J, Villalobos P, Sepesi B, Weissferdt A, Kalhor N, Heymach J, Moran C, Gibbons DL, Wistuba I. Sex Differences are Detected in the Profile of Tumor Associated Inflammatory Cells (TAICS) are Lung Adenocarcinoma. J Thorac Oncol 12(S1):S161-S162, 2017. e-Pub 2017.
31. Tran H, Zhang J, Vasquez M, Fossella F, Simon G, Tsao A, Gibbons DL, Elamin Y, Banks K, Lanman R, Papadimitrakopoulou V, Heymach J. Retrospective Review Clinical Use of A CFDNA Blood Test for Identification of Targetable Molecular Alterations in Patients with Lung Cancer. J Thorac Oncol 12(S1):S498, 2017. e-Pub 2017.
32. Parra E, Villalobos P, Zhang J, Behrens C, Mino B, Moran C, Swisher S, Sepesi B, Weissferdt A, Kalhor N, Heymach J, Lee J, Zhang J, Gibbons DL, Rodrigues-Canales J, Wistuba I. Image Analysis-Based Expression of Nine Immune Checkpoints Identifies Distinct Immunoprofiling Patterns in Non-Small Cell Lung Carcinomas. J Thorac Oncol 12(S1):S429, 2017. e-Pub 2017.
33. Roszik J, Gibbons DL, Heymach J, Vaporciyan A, Swisher S, Sepesi B. Lung Cancer PD-L1 MRNA Expression Profile and Clinical Outcomes - An Analysis from the Cancer Genome Atlas and Cancer Cell Line Encyclopedia. J Thorac Oncol 12(S1):S426, 2017. e-Pub 2017.
34. Tang H, Zhang J, Hu X, Xu Y, Dong B, Wang J, Kong Y, Ma H, Liao Z, Zhang J, Byers LA, Gibbons DL, Glisson BS, Wistuba I, Heymach J, Gomez DR, Futreal A, Chen M. EGFR Mutations in Small Cell Lung Cancer (SCLC): Genetic Heterogeneity and Prognostic Impact 12(S1):S367, 2017. e-Pub 2017.
35. Sepesi B, Team I, Heymach J, Sharma P, Allison J, Fang B, Zhang J, Wagner H, Bogatenkova E, Wistuba I, Swisher S, Bernatchez C, Gibbons DL. Prospective Immunogenomic Profiling of Non-Small Cell Lung Cancer- The ICON Project. J Thorac Oncol 12(S1):S165, 2017. e-Pub 2017.
36. Jalali A, Wang J, Lee WC, Zhang J, Wu CC, Gibbons DL, Tang XM, Kalhor N, Izzo J, Behrens C, Fossella FV, Tsao AS, Lee JJ, Swisher S, Heymach J, Futreal A, Wistuba II, Herbst RS, Papadimitrakopoulou V, Zhang J. Interplay between Immune Infiltration and Tumor Progression and Survival in Non-Small Cell Lung Cancer: An Analysis of Institutional and Public Data, 2017. e-Pub 2017.
37. Chen L, Byers LA, Ullrich S, Wistuba II, Qin XF, Gibbons DL. CD38 as a Novel Immune Checkpoint and a Mechanism of Resistance to the Blockade of the PD-1/PD-L1 Axis, 2017. e-Pub 2017.
38. Denning WL, Skoulidis F, Shen L, Papadimitrakopoulou V, Diao L, Lou Y, Byers LA, Wang J, Canales JR, Wistuba II, Weinstein J, Gibbons DL, Heymach JV. Loss of LKB1 Mediates an Immune Inert Phenotype in Human Lung Adenocarcinoma. AACR Annual Meeting 2016, New Orleans, LA, 2016. e-Pub 2016.
39. Kudinov A, Deneka A, Nikonova A, Serebriiskii I, Beck TN, Cai Q, Egleston BL, Nicolas E, Borghaei H, Gibbons DL, Kurie J, Golemis EA, Boumber Y. Musashi-2 (MSI2) Drives TGFBR1/SMAD3 Dependent Partial EMT and Supports VEGFR2 Expression and Metastasis of Human and Mouse NSCLC Cells. AACR Annual Meeting 2016, New Orleans, LA, 2016. e-Pub 2016.
40. Choi M, Kadara H, Zhang J, Cuentas EP, Rodriguez Canales J, Gaffney SG, Zhao ZM, Behrens C, Fujimoto J, Chow CW, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach JV, Kaftan E, Townsend J, Lynch TJ, Schlessinger J, Lee JJ, Lifton R, Herbst RS, Wistuba II. Mutation and Immune Profiles in Early-Stage Lung Squamous Cell Carcinoma. AACR Annual Meeting 2016, New Orleans, LA, 2016. e-Pub 2016.
41. Kadara H, Choi M, Zhang J, Cuentas EP, Rodriguez Canales J, Gaffney S, Zhao ZM, Behrens C, Fujimoto J, Chow CW, Kalhor N, Moran C, Rimm D, Swisher SG, Gibbons DL, Heymach JV, Kaftan E, Townsend J, Lynch TJ, Schlessinger J, Lee JJ, Lifton R, Wistuba II, Herbst RS. Whole-Exome Sequencing and Immune Profiling of Early-Stage Lung Adenocarcinoma. AACR Annual Meeting 2016, New Orleans, LA, 2016. e-Pub 2016.
42. Sen T, Tong P, Stewart A, Cristea S, Fan YH, Glisson BS, Gibbons DL, Sage J, Wang J, Byers LA. Exploiting the G2-M Cell Cycle Checkpoint Dependency in Small Cell Lung Cancer (SCLC) using Pharmacological Inhibitors of CHK1 and WEE1. AACR The Cancer Cell Cycle: Tumor Progression and Therapeutic Response, Orlando, FL, 2016. e-Pub 2016.
43. Tran HT, Elamin Y, Simon GR, Blumenschein GR, Tsao AS, Papadimitrakopoulou V, Gibbons DL, Fossella FV, Lanman RB, Banks KC, Byers LA, Zhang J, Heymach J. Clinical Utilization of a CLIA-Certified Cell-Free DNA (cfDNA) Blood Test for Identification of Targetable Molecular Alterations in Patients with Non-Small Cell Lung Cancer (NSCLC). J Clin Oncol 34(suppl; abstr e23064), 2016. e-Pub 2016.
44. Kundu ST, Grzeskowiak C, Creighton CJ, Scott KL, Gibbons DL. Identifying TMEM106B as A Novel Metastasis Driver in Non-Small Cell Lung Cancers through an In Vivo Gain-of-Function Screen. AACR Annual Meeting 2016, New Orleans, LA, 2016. e-Pub 2016.
45. Gay CM, Kundu S, Diao L, Glisson B, Wang J, Heymach JV, Byers LA, Gibbons DL. Unique MicroRNA Signatures in Small Cell Lung Cancer Correlate with Distinct Protein Expression Profiles and Drug Response. AACR Annual Meeting 2016, New Orleans, LA, 2016. e-Pub 2016.
46. Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Camidge DR, Doebele RC, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Komaki R, Louie AV, Palma DA, Tsao AS, William WN, Zhang J, Swisher S, Heymach J. Local Consolidative Therapy (LCT) to Improve Progression-Free Survival (PFS) in Patients with Oligometastatic Non-Small Cell Lung Cancer (NSCLC) who Receive Induction Systemic Therapy (IST): Results of a Multi-Institutional Phase II Randomized Study. J Clin Oncol 34(suppl; abstr 9004), 2016. e-Pub 2016.
47. Tang H, Zhang J, Hu X, Xu Y, Dong B, Kong Y, Zhang X, Liao ZX, Zhang J, Byers LA, Gibbons DL, Glisson BS, Wistuba II, Heymach J, Gomez DR, Futreal A, Chen M. Preliminary Analysis of Genomic Profiling of Small Cell Lung Cancer in Chinese Population Revealed Frequent PIK3CA Hotspot Mutations. J Clin Oncol 34(suppl; abstr e20089), 2016. e-Pub 2016.
48. Zhang J, Fujimoto J, Yusko E, Zhang J, Vignali M, Song X, Rodriguez-Canales J, Parra Cuentas ER, Behrens C, Benzeno S, Robins H, Gibbons DL, Swisher S, Heymach J, Futreal A, Wistuba II. Intra-tumor Heterogeneity of T Cell Receptor Repertoire in Lung Cancers and its Association with Tumor Genomic Profile. J Clin Oncol 34(suppl; abstr 8539), 2016. e-Pub 2016.
49. Gibbons DL, Chow LQ, Kim DW, Kim SW, Yeh TC, Song X, Jiang H, Taylor R, Karakunnel JJ, Creelan B. Efficacy, Safety and Tolerability of MEDI4736 (durvalumab), A Human Igg1 PD-L1 Antibody, Combined with Gefitinib: A Phase I Expansion in TKI-naïve Patients with EGFR Mutant NSCLC. ALCC 2016 congress, 2016. e-Pub 2016.
50. Tran HT, Elamin Y, Simon GR, Blumenschein GR, Tsao AS, Papadimitrakopoulou V, Gibbons DL, Fossella FV, Lanman RB, Banks KC, Byers LA, Zhang J, Heymach J. Clinical Utilization of A CLIA-Certified Cell-Free DNA (cfDNA) Blood Test for Identification of Targetable Molecular Alterations in Patients with Non-Small Cell Lung Cancer (NSCLC). J Clin Oncol 34(suppl; abstr e23064), 2016. e-Pub 2016.
51. Lou Y, Diao L, Byers LA, Gibbons DL, Denning W, Wang J, Papadimitrakopoulou V, Wistuba II, Goswami S, Cortez MA, Welsh J, Kurie JM, Heymach JV. Epithelial-Mesenchymal Transition is Associated with a Profound Inflammatory Tumor Microenvironment in Lung Adenocarcinoma. IASLC 16th World Conference on Lung Cancer, Denver, CO, 2015. e-Pub 2015.
52. Mak MP, Diao L, Tong P, Wang J, Ng PK, Cardnell RJ, Hayes DN, Robertson G, Myers JN, El-Naggar A, William WN, Coombes KR, Weinstein JN, Mills GB, Heymach JV, Gibbons DL, Byers LA. Enriched Expression of PD-L1 and Other Immune Targets after Epithelial-Mesenchymal Transition (EMT) in Squamous Head and Neck and Lung Cancers. 2015 ASCO Annual Meeting, Chicago, Illinois, 2015. e-Pub 2015.
53. Lou Y, Diao L, Cuentas P, Roger E, Denning WL, Chen L, Fan YH, Rodriguez J, Byers, LA, Wang J, Papadimitrakopoulou V, Carmen B, Wistuba II, Hwu P, Heymach JV, Gibbons DL. Epithelial-Mesenchymal Transition is Associated with a Profound Inflammatory Tumor Microenvironment in Lung Adenocarcinoma. 2015 AACR Annual Meeting, Philadelphia, PA, 2015. e-Pub 2015.
54. Denning WL, Diao L, Skoulidis F, Lou Y, Byers LA, Wang J, Weinstein J, Gibbons DL, Heymach JV. Defined Co-Mutation Subgroups of KRAS-Mutated NSCLC Display Distinct Immune Profiles. 2015 AACR Annual Meeting, Philadelphia, PA, 2015. e-Pub 2015.
55. Valliani AA, Sen T, Masrorpour F, Diao L, Cardnell RJ, Wang J, Glisson BS, Piwnica-Worms H, Gibbons DL, Byers LA. Check Point Kinase 1 (Chk1) Targeting as A Novel Therapeutic Strategy in Small Cell Lung Cancer (SCLC). 2015 AACR Annual Meeting, Philadelphia, PA, 2015. e-Pub 2015.
56. Chen L, Lou Y, Heymach J, Wistuba I, Ullrich S, Qin XF, Gibbons DL. Targeting the EMT-Immunosuppression Loop in Lung Cancer as a Strategy to Prevent Metastasis. AACR Tumor Metastasis, Austin, TX:29, 2015. e-Pub 2015.
57. Peng DH, Tong P, Byers LA, Wang J, Creighton CJ, Gibbons DL. Zeb1 Induces LOXL2-Mediated Collagen Stabilization and Deposition in the Extracellular Matrix to Drive Lung Cancer Invasion and Metastasis. AACR Tumor Metastasis, Austin, TX:52, 2015. e-Pub 2015.
58. Kundu ST, Grzeskowiak C, Creighton CJ, Scott KL, Gibbons DL. A Novel in vivo Gain-of-Function Screen for Metastasis Drivers in Non-Small Cell Lung Cancers. AACR Tumor Metastasis, Austin, TX:79, 2015. e-Pub 2015.
59. Mak MP, Tong P, Diao L, Ng PKS, Fan Y, Cardnell RJ, Gibbons DL, William WN, Heymach JV, Coombes KR, Byers LA, Wang J. A Pan-Cancer Tumor-Derived Epithelial-To-Mesenchymal Transition (EMT) Signature Determines Patterns of Drug Sensitivity and Enrichment in Immune Target Expression Following EMT. 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain, 2014. e-Pub 2014.
60. Kundu ST, Wu P, Creighton CJ, Scott KL, Gibbons DL. High-Throughput Functional Screen for Metastasis Drivers in Lung Cancer. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 2014. e-Pub 2014.
61. Lou Y, Diao L, Byers LA, Gibbons DL, Denning W, Wang J, Papadimitrakopoulou V, Wistuba II, Goswami S, Cortez MA, Welsh J, Kurie JM, Heymach JV. Association of Epithelial-Mesenchymal Transition Status with PD1/PDL1 Expression and a Distinct Immunophenotype in Non-Small Cell Lung Cancer: Implications for Immunotherapy Biomarkers. 2014 ASCO Annual Meeting, Chicago, Illinois, 2014. e-Pub 2014.
62. Gibbons DL, Chen L, Goswami S, Cortez MA, Ahn YH, Byers LA, Lin W, Diao L, Wang J, Roybal J, Ungewiss C, Antonia SJ, Mediaville-Varela M, Suraokar MB, Welsh J, Chen L, Wistuba II, Heymach JV, Kurie JM, Qin XF. Regulation of Tumor Cell PD-L1 Expression by Microrna-200 and Control of Lung Cancer Metastasis. 2014 ASCO Annual Meeting, Chicago, Illinois, 2014. e-Pub 2014.
63. Mishra DK, Thrall MJ, Creighton CJ, Gibbons DL, Kurie JM, Kim MP. A549 and H1299 Cells form Metastatic Lesions in the Ex Vivo 4D Lung Cancer Model. 9th Annual Academic Surgical Congress, San Diego, California, 2014. e-Pub 2014.
64. Gibbons DL, Chen L, Goswami S, Ahn YH, Byers LA, Diao L, Wang J, Cortez A, Roybal JD, Welsh J, Zhang X, Dwyer D, Yi X, Lieping C, Wistuba II, Heymach JV, Kurie JM, Qin FX. Microrna-200 Regulates Tumor Cell PD-L1 Expression to Control Lung Cancer Metastasis. Clinical Cancer Research, 2014. e-Pub 2014.
65. Gibbons DL, Chen L, Goswami S, Ahn YH, Byers LA, Diao L, Wang J, Cortez A, Roybal J, Welsh J, Zhang X, Dwyer D, Yi X, Lieping C, Wistuba II, Heymach JV, Kurie JM, Qin FX. Microrna-200 Regulates Tumor Cell PD-L1 Expression to Control Lung Cancer Metastasis. AACR-IASLC Joint Conference on The Molecular Origins of Lung Cancer, San Diego, California, 2014. e-Pub 2014.
66. Byers LA, Diao L, Wang J, Gibbons DL, Robertson G, Cardnell RJ, Masrorpour F, Fan YH, Rodriguez J, Tang X, Weinstein JN, Minna JD, Wistuba II, Mills GB, Heymach JV. Targeting EMT in Lung Cancer: An Integrated Analysis of Axl and Other Mesenchymal Targets in the Cancer Genome Atlas (TCGA). IASLC 15th World Conference on Lung Cancer (WCLC 2013), Sydney, Australia, 2013. e-Pub 2013.
67. Mishra DK, Creighton C, Thrall MJ, Zhang Y, Gibbons DL, Kurie JM, Kim MP. Circulating Tumor Cells from 4D Model Mimic Metastatic Pattern In Vivo and Gene Expression Profile Predicts Poor Prognosis in Lung Cancer Patients. IASLC 15th World Conference on Lung Cancer (WCLC 2013), Sydney, Australia, 2013. e-Pub 2013.
68. Mak MP, Valliani A, Cardnell RJ, Bailey AM, Eterovic AK, Zhao H, Chen K, Wistuba II, Meric-Bernstam F, Mills GB, Byers LA, Gibbons DL. Molecular Evolution of Lung Adenocarcinoma in A Young Never-Smoker Patient. 2013 Symposia on Cancer Research, Genomic Medicine, Houston, Texas, 2013. e-Pub 2013.
69. Ungewiss C, Roybal J, Peng DH, Gibbons DL. Microrna-200 Family Control of Matrix-Dependent Tumor Cell Activation, Cytoskeletal Changes and Invasion. The University of Texas MD Anderson Cancer Center Trainee Research Day, Houston, Texas, 2013. e-Pub 2013.
70. Kundu ST, Gibbons DL. Role of FOXF2 as A Novel Driver of EMT and Metastasis. The University of Texas MD Anderson Cancer Center Trainee Research Day, Houston, Texas, 2013. e-Pub 2013.
71. Gold KA, Byers LA, Fan YH, Fujimoto J, Tse WH, Lee JJ, Gupta S, Wistuba II, Stewart DJ, Gibbons DL. A Phase I/II Trial Combining Erlotinib with Gamma Secretase Inhibitor RO4929097 in Advanced Non-Small Cell Lung Cancer (NSCLC). 2013 ASCO Annual Meeting, Chicago, Illinois, 2013. e-Pub 2013.
72. Kundu ST, Ahmad S, Shin DH, Creighton CJ, Byers LA, Gibbons DL. Role of FOXF2 as A Novel Driver of EMT and Metastasis. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 2013. e-Pub 2013.
73. Gibbons DL, Ungewiss C, Peng DH, Rizvi ZH, Byers LA, Robertson G. Microrna-200 Controls Matrix Deposition and Matrix-Dependent SRC Signaling to Produce Tumor Cell Invasion. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 2013. e-Pub 2013.
74. Ungewiss C, Roybal JD, Peng DH, Gibbons DL. MIR-200 Control of Tumor Cell Cytoskeletal Changes and Invasion. AACR Tumor Invasion and Metastasis Conference, San Diego, California, 2013. e-Pub 2013.
75. Roybal JD, Peng DH, Ungewiss C, Gibbons DL. The Role of the Microrna-200 Family in the Regulation of Tumor-Cell Signaling and Metastasis in Lung Cancer. AACR Tumor and Invasion and Metastasis Conference, San Diego, California, 2013. e-Pub 2013.
76. Roybal JD, Peng DH, Ungewiss C, Gibbons DL. The Role of the Microrna-200 Family in the Regulation of Tumor-Cell Integrin Expression and Metastasis in Lung Cancer. Gordon Conference on Signaling and Adhesion Molecules, Waterville, Maine, 2012. e-Pub 2012.
77. Ungewiss C, Roybal JD, Gibbons DL. MIR-200 Control of Tumor Cell Cytoskeletal Changes and Invasion. Gordon Conference on Signaling and Adhesion Molecules, Waterville, Maine, 2012. e-Pub 2012.
78. Roudsari LC, Gill BJ, Gibbons DL, Kurie JM, West JL. A Model of Tumor Angiogenesis in Biomimetic Hydrogels. Biomedical Engineering Society Annual Meeting, Atlanta, Georgia, 2012. e-Pub 2012.
79. Chatterjee S, Feigin M, Siefred L, Gibbons DL, Claudio S, Lin W, Rizvi ZH, Kurie J, Lind E, Ohashi P, Muthuswamy SK. Loss of Multiple Cell Polarity Regulators Synergizes with Pro-Tumorigenic Conditions to Promote Invasion. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 2011. e-Pub 2011.
80. Gill BJ, Saik JE, Rizvi ZH, Gibbons DL, Kurie JM, West JL. Matrix-Derived Metastatic Cues in a Poly(Ethylene Glycol)- Based Hydrogel System. Society for Biomaterials Annual Conference, Orlando, Florida, 2011. e-Pub 2011.
81. Rizvi ZH, Muthuswamy SK, Kurie JM, Gibbons DL. The Scribble Polarity Complex Modulates Tumor Cell Invasion by Regulation of the Zeb1/Mir-200 Axis and Dampening of B1-Integrin Signaling. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 2011. e-Pub 2011.
82. Rizvi ZH, Schliekelman MJ, Gill BJ, Saik JE, Creighton CJ, Gregory PA, Goodall GJ, Hanash SM, West JL, Muthuswamy SK, Kurie JM, Gibbons DL. Microrna-200 Acts as an Epithelial Maintenance Factor and Metatasis Suppressor by Blocking Cell-Intrinsic and Extracellular Matrix Changes. Keystone Symposia, Vancouver, Canada, 2011. e-Pub 2011.
83. Pricl S, Gibbons DL, Posocco P, Laurini E, Fermaglia M, Kantarjian HM, Talpaz M, Cortes J, Donato N, Quintas-Cardama. The Novel BCR-ABL1 V304D Mutation Induces Pan-Tyrosine Kinase Inhibitor Resistance by a Unique Kinase Lateral Escape Mechanism and is Associated with Very Poor Prognosis in Patients with Chronic Myeloid Leukemia. American Society of Hematology, Orlando, Florida, 2010. e-Pub 2010.
84. Pricl S, Gibbons DL, Posocco P, Laurini E, Fermeglia M, Kantarjian H, Talpaz M, Cortes J, Donato N, Quintas-Cardama A. In Silico Modeling of Sensitivity to Novel Tyrosine Kinase Inhibitors of Highly Resistant Single-Point Mutant and Polymutant BCR-ABL1 Proteins. American Society of Hematology, Orlando, Florida, 2010. e-Pub 2010.
85. Rizvi ZH, Ahn YH, Creighton CJ, Goodall G, Gregory PA, Kurie J, Gibbons DL. The Scribble Polarity Complex Modulates Tumor Cell Invasion by Regulation of the Zeb1/Mir-200 Axis and Dampening of B1-Integrin Signaling. American Association for Cancer Research, Philadelphia, Pennsylvania, 2010. e-Pub 2010.
86. Gibbons DL, Yang Y, Ahn YH, Pertsemlidis A, Gregory PA, Creighton CJ, Lin W, Rizvi ZH, Kurie J. EMT and Metastasis in a Murine Model of NSCLC is Dependent upon the Notch Ligand Jagged2 Activation of a GATA3-Mir-200 Feedback Loop. American Association for Cancer Research, Philadelphia, Pennsylvania, 2010. e-Pub 2010.
87. Rizvi ZH, Gibbons DL, Chad CJ, Gregory PA, Kurie JM. The Role of the Microrna-200 Family in Zeb1-Induced Epithelial-Mesenchymal Transition and Metastases in a P53/K-Ras Murine Model of Lung Adenocarcinoma. American Association for Cancer Research, Arlington, Virginia, 2010. e-Pub 2010.
88. Gibbons DL, Yang Y, Ahn YH, Pertsemlidis A, Gregory PA, Creighton CJ, Lin W, Rizvi ZH, Kurie J. EMT and Metastasis in a Murine Model of NSCLC is Dependent upon the Notch Ligand Jagged2 Activation of a GATA3-Mir-200 Feedback Loop. American Association for Cancer Research, Arlington, Virginia, 2010. e-Pub 2010.
89. Gibbons DL, Gregory PA, Lin W, Creighton C, Kurie JM. A Murine Model of NSCLC Demonstrates A Role for the Mir-200 Family in Regulating EMT & Metastasis. Keystone Symposium, Keystone, Colorado, 2009. e-Pub 2009.
90. Quintas-Cardama A, Gibbons DL, Kantarjian H, Talpaz M, Donato N, Cortes J. Mutational Analysis of Chronic Myeloid Leukemia Clones Reveals Heightened BCR-ABL1 Genetic Instability and Wild-type BCR-ABL1 Exhaustion in Patients Failing Sequential Imatinib and Dasatinib Therapy. American Society of Hematology, San Francisco, California, 2008. e-Pub 2008.
91. Lin W, Gibbons DL, Kurie JM. Identifying Novel Genetic Changes Associated with Metastasis using a New Murine Model of Metastatic Non-small Cell Lung Cancer. Winter Lung SPORE Meeting, Santa Monica, California, 2008. e-Pub 2008.
92. Gibbons DL, Lin W, Kurie JM. The Development and Characterization of a New Experimental Mouse Model to Study Metastatic Non-small Cell Lung Cancer. Winter Lung SPORE Meeting, Santa Monica, California, 2008. e-Pub 2008.
93. Quintas-Cardama A, Gibbons DL, Hagop K, Talpaz M, Cortes J, Donato N. Sequencing of Subcloned PCR Products Facilitates Earlier Detection of BCR-ABL1T3151 Mutants Compared to Direct Sequencing of the ABL1 Kinase Domain. American Society of Hematology, Atlanta, Georgia, 2007. e-Pub 2007.
94. Quintas-Cardama A, Gibbons DL, Kantarjian H, Talpaz M, Cortes J, Donato N. Mutations within BCR-ABL1 295-312 Define a Novel Region Associated with Poor Prognosis in Patients with Chronic Myelogenous Leukemia Resistant to Imatinib. American Society of Hematology, Atlanta, Georgia, 2007. e-Pub 2007.

Book Chapters

1. Gomes DBD, Gold KA, Gibbons DL. Non-Small Cell Lung Cancer. In: The MD Anderson Manual of Medical Oncology. Third. McGraw Hill Education, 343-376, 2016.
2. Gibbons DL, Rizvi ZH, Kurie JM. MicroRNAs in Cancer Translational Research. In: The Role of microRNAs in Lung Cancer Development, Progression and Metastasis. 1st. Springer Press, 557, 2011.
3. Gibbons DL, Pisters KMW, Johnson FM. Non-Small Cell Lung Cancer. In: The MD Anderson Manual of Clinical Oncology, 2011.
4. Gibbons DL, Wolff RA, and Varadhachary G. Targeted Drug Therapy in Pancreatic Cancer. In: Targeted Cancer Therapy, 2008.
5. Cascone T, Fradette J, Pradhan M, Gibbons DL. The Science of Lung Cancer and Potentials for Clinical Translation. In: Tumor Immunology and Immunotherapy of Non-small Cell Lung Cancer. Cold Spring Harbor Laboratory Press.
6. Elamin YY, Gibbons DL, Negrao MV. The MD Anderson Manual of Medical Oncology. In: Targeted Therapies in Non-Small Cell Lung Cancer. 4. McGraw Hill Education.

Books (edited and written)

1. Quintas-Cardama A, Gibbons DL, Cataldo VD. Targeted Therapy for Solid Tumors and Hematologic Malignancies. Nova Biomedical, 2011.

Letters to the Editor

1. Quintás-Cardama A, Gibbons DL. Five-gene Signature in Non-small-cell Lung Cancer. N Engl J Med 356: 1582-3; author reply 1583, 2007.